US 5,095,129 AGrant
19,11 .Beta.-Bridged Steroids, Their Manufacture and Pharmaceutical Preparations Containing Them
Issue Date:1992-03-10
•27 Claims
•2 Drawing Sheets
Abstract
New 19,11.beta.-bridged steroids of the general formula I ##STR1## where R.sup.1 stands for a methyl or ethyl radical, are described as well as their pharmaceutically tolerated addition salts with acids. The new compounds possess valuable pharmacological properties. R.sup.2 for a hydrogen or chlorine atom or a C.sub.1 -C.sub.4 -alkyl radical, B and G, which are the same or different, respectively for a hydrogen atom, a C.sub.1 -C.sub.4 -alkyl radical or, together, for a second bond between the carbon atoms 6 and 7, B and R.sup.2 together for a methylene or an ethylene group, Z for the radical of a pentagonal or hexagonal ring, which is possibly substituted and possibly unsaturated, V stands for a possibly substituted carbocyclic or heterocyclic aryl radical, the ring A for ##STR2## M and N together meaning a second bond or M a hydrogen atom and N a hydroxy group, X means an oxygen atom, two hydrogen atoms or a hydroxyimino grouping N.about.OH, R.sup.3 and D, which are the same or different, respectively a hydrogen atom, a nitrile radical or a C.sub.1 -C.sub.4 -alkyl radical or, together, a methylene or ethylene group, E a hydrogen atom or a C.sub.1 -C.sub.4 -alkyl radical, D and E together meaning a second bond between carbon atoms 1 and 2 or together a methylene group ##STR3## with R.sup.11 in the meaning of a hydrogen atom or a C.sub.1 -C.sub.8 -alkyl radical,
Metadata
Assignee
- Schering Aktiengesellschaft
Inventors
- Eckhard Ottow
- Rudolf Wiechert
- Gunter Neef
- Sybille Beier
- Walter Elger
- David A. Henderson
Application Information
Application Number:US 2836327
Filing Date:1988-12-09
Priority Date:1987-03-18
Art Unit:124
Classifications
IPC:
C07J 5300C07J 4300
Field of Search:
260352514397.45;397.4510172;76;78;179
Patent Drawings (2 sheets)
Description
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 illustrates the influence of selected compounds given s.c. upon dexamethasone-induced thymus suppression in adrenalectomized male rats (b.w. 100-130 g). The graphs show treatment for four days (dose mg/d) with thymus weight determined on day 5.
FIG. 2 also shows the influence of selected compounds given s.c. upon dexamethasone-induced thymus suppression in adrenalectomized male rats (b.w. 100-130 g). Treatment again was for 4 days (dose mg/d) with thymus weight determined on day 5.
EXAMPLES
In the following examples the chromatography is performed with a mixture of acetic ester and hexane, unless otherwise indicated.
EXAMPLE 1
17.beta.-hydroxy-11.beta.,19-(o-phenylene)-4-androsten-3-one
a) 19-(2-chlorophenyl)-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-androstene-5 .alpha.,17.beta.-diol
4.9 g of magnesium chips are added to 40 ml of abs. diethyl ether under inert gas, then mixed with 0.5 ml of 2-chlorobenzyl chloride and subsequently carefully mixed with 0.4 ml of 1,2-dibromomethane. After the reaction starts the remaining amount (18.4 ml) of the 2-chlorobenzyl chloride, dissolved in 135 ml of abs. diethyl ether, is added dropwise in the course of 40 minutes time without the temperature inside the reaction vessel rising above 30.degree. C. After Grignard's reagent is formed the reaction mixture is cooled to 0.degree. C. and 5.alpha.,10.alpha.-epoxy-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-estren- 17.beta.-ol (13.6 g), dissolved in 75 ml of abs. tetrahydrofurane, is slowly added dropwise. After subsequent stirring in an ice bath the reaction mixture is slowly heated overnight to room temperature and then poured over diluted ammonium chloride solution. The aqueous phase is extracted several times with acetic ester. The combined organic phases are washed neutral with a sodium-chloride solution, dried with sodium sulfate and concentrated in vacuo. The residue is chromatographed over aluminum oxide (neutral, stage III). This yields 14.8 g of the above compound.
[.alpha.].sub.D.sup.22 =-2.degree. (CHCl.sub.3 ; c=0.51)
Flash point: 188.degree.-191.degree. C. (ethylacetate)
b) 11.beta.,19-(o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-androstane-5 .alpha.,17.beta.-diol
600 ml of anhydrous ammonia are concentrated in the reaction flasks at -65.degree. C., with all moisture excluded, and mixed with 970 mg of freshly cut lithium chips. Immediately after development of the characteristic blue color a solution of 14 g of the product obtained in accordance with a) are added dropwise to 450 ml of abs. tetrahydrofuran in such a way that the reaction solution alternates between a colorless and a blue state. After addition, the surplus lithium is eliminated by adding ethanol dropwise, most of the ammonia removed by evaporation and the reaction mixture poured into water. The aqueous phase is extracted with acetic ester. The combined organic phases are washed neutral with a sodiumchloride solution, dried with sodium sulfate and concentrated in vacuo. Chromatography over aluminum oxide (neutral, stage III). This yields 10.3 g of the above compound.
[.alpha.].sub.D.sup.22 =+13.degree. (CHCl.sub.3 ; c=0.52)
Fp.: =164.degree.-167.degree. C. (ethylacetate)
.sup.1 H-NMR (CDCl.sub.3) [.delta.]: 7.0-7.45 (4H, m, aromatic protons); 3.13 (1H, d J=16 Hz, proton on C-19); 2.68 (1H, d J=16 Hz, proton on C-19); 0.98 (3H, s, protons of a ketalmethyl group); 0.95 (3H, s, protons of a ketalmethyl group); 0.25 (3H, s, protons on C-18).
The title compound indicated in b) can also be prepared in the following way:
.alpha.) 19-(2-bromophenyl)-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-androstene-5. alpha.,17.beta.-diol
Analogous to Example 1a) 5 g of 5.alpha.,10.alpha.-epoxy-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-estren- 17.beta.-ol are allowed to react with 26.7 g of 2-bromobenzyl bromide. After chromatography this yields 5.9 g of the above compound in the form of white foam.
.sup.1 H-NMR (CDCl.sub.3) [.delta.]: 6.95-7.55 (4H, m, protons on the aromatic compound); 5.45 (1H, s wide, proton on C-11); 3.7-3.82 (1H, m, proton on C-17); 3.4-3.6 (4H, m, protons of the ketalmethylene groups); 3.16 and 3.07 (each [1H, d with 15 Hz cleavage], A,B system of protons on C-19); 0.98 (3H, s, protons of a ketalmethyl group); 0.9 (3H, s, protons of a ketalmethyl group); 0.55 (3H, s, protons on C-18).
.beta.) 11.beta.,19-(o-phenylene)-3.3-(2,2-dimethyltrimethylenedioxy)-androstane-5 .alpha.,17.beta.-diol
2.5 g of the compound obtained in accordance with .alpha.) are dissolved in 250 ml of absolute toluene, mixed with 2.25 ml of tributyltin hydride and 250 mg of .alpha.,.alpha.-azoisobutyronitrile and heated for 3 hours under reflux. The solvent is then removed in vacuo, the residue taken up in tetrahydrofuran and stirred with 50 ml of saturated aqueous potassium-fluoride solution for one hour. The aqueous phase is then extracted with acetic ester and eliminated. The organic phases are combined, dried over sodium sulfate and concentrated in vacuo. The residue is chromatographed over aluminum oxide (neutral, stage III). This yields 1.75 g of the title compound.
The title compound indicated in b) can also be prepared from the following compound:
.gamma.) 19-(2-fluorophenyl)-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-androstene-5 .alpha., 17.beta.-diol
Analogous to Example 1a) 750 mg of 5.alpha.,10.alpha.-epoxy-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-estren- 17.beta.-ol are allowed to react with 2 g of 2-fluorobenzyl chloride. After chromatography this yields 798 mg of the above compound in the form of white foam.
.sup.1 H-NMR (CD.sub.2 Cl.sub.2) [.gamma.]: 6.92-7.33 (4H, m, protons on the aromatic compound); 5.09 (1H, m, proton on C-11); 3.62-3.72 (1H, m, proton on C-17); 3.45-3.58 (4H, m, protons of the ketalmethylene groups); 2.97 and 2.9 (each [1H, d with 15 Hz cleavage], A,B system of protons on C-19); 0.99 (3H, s, protons of a ketalmethyl group); 0.9 (3H, s, protons of a ketalmethyl group); 0.61 (3H, s, protons on C-18).
.delta.) 11.beta.,19-(o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-androstane-5 .alpha.,17.beta.-diol
Analogous to Example 1b) 750 mg of 19-(2-fluorophenyl)-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-androstene-5 .alpha.,17.beta.-diol are allowed to react with 60 mg of lithium. After chromatography 585 mg of the above compound are isolated in the form of white foam.
c) 17.beta.-hydroxy-11.beta.,19-(o-phenylene)-4-androsten-3-one
2 g of the product obtained in accordance with b) are dissolved in 100 ml of acetone and mixed with 5 ml of 4 n hydrochloric acid. After stirring for four hours at room temperature the reaction mixture is poured over saturated sodium hydrogen carbonate solution and the aqueous phase extracted with methylene chloride. The combined organic phases are dried with sodium sulfate and concentrated in vacuo. The residue is chromatographed over silica gel. This yields 1.13 g of the above compound.
[.alpha.].sub.D.sup.22 =+84.degree. (CHCl.sub.3 ; c=0.5)
.sup.1 H-NMR (CDCl.sub.3) [.delta.]: 7-7.5 (4H, m, protons on the aromatic compound); 5.88 (1H, s, proton on C-4); 3.68 (1H, tr J=9 Hz, proton on C-17); 3.3 (1H, m, proton on C-11); 3.26 (1H d J=17 Hz, proton on C-19); 2.74 (1H, d J.sub.1 =17 Hz, proton on C-19); 0.29 (3H, s, protons on C-18).
EXAMPLE 2
17.beta.-hydroxy-17-(prop-1-inyl)-11.beta.,19-(o-phenylene)-4-androsten-3-o ne
a) 11.beta.,19-(o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimethyltrimethylenedi oxy)-androstan-17-one
11.28 g of chromium trioxide are added in portions to a mixture of 34.3 ml of pyridine and 287 ml of methylene chloride at 0.degree. C. The steroid obtained in accordance with Example 1b) (8 g) is subsequently dissolved in 50 ml of methylene chloride, slowly added dropwise to the reaction mixture at the same temperature and the latter stirred for another two hours at the temperature of an ice bath. After the stirring is finished the solid constituents of the reaction are precipitated, the supernatant decanted and the precipitate washed out thoroughly several times with methylene chloride. The combined organic phases are liberated from remaining inorganic constituents by washing with an aqueous 0.5 m potassium-hydroxide solution, washed neutral with water, dried over sodium sulfate and concentrated in vacuo. 7 g of raw 11.beta.,19-(o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimethyltrimethylenedi oxy)-androstan-17-one are isolated, the purity of which is suitable for further reactions (see below). 500 mg are purified for analytical purposes by chromatography over aluminum oxide (neutral, stage III). 432 mg of the desired product are isolated.
[.alpha.].sub.D.sup.22 =+31.degree. (CHCl.sub.3 ; c=0.505)
Fp.: =206.degree.-210.degree. C. (ethylacetate)
b) 17-(prop-1-inyl)-11.beta.,19-(o-phenylene)-3,3-(2,2-dimethyltrimethylenedi oxy)-androstane-5.alpha.,17.beta.-diol
225 ml of abs. tetrahydrofuran are saturated with propine at 0.degree. C. 1.6 m of n-butyllithium solution (hexane) (27.7 ml) is subsequently slowly added dropwise to this solution without significantly raising the temperature. After subsequent stirring for fifteen minutes a solution of 2 g of the raw product obtained in accordance with a), in 45 ml of abs. tetrahydrofuran, are slowly added dropwise to this reaction solution and subsequently stirred for 30 minutes. Afterwards the reaction mixture is poured into water, the aqueous phase extracted with acetic ester and the combined organic phases washed with a solution of sodium chloride. Drying over sodium sulfate and concentration in vacuo yield 2.44 g of the raw product. Chromatography over aluminum oxide (neutral, stage III) yields 1.8 g of the above compound.
IR (KBr): 2230 cm.sup.-1 triple bond
c) 17.beta.-hydroxy-17-(prop-1-inyl)-11.beta.,19-(o-phenylene)-4-androsten-3- one
Analogous to the acid cleavage described in Example 1c) 1.5 g of the product obtained in accordance with b) are converted to yield 738 mg of the title compound.
EXAMPLE 3
17.beta.-hydroxy-17-(prop-1-inyl)-11.beta.,19-(o-phenylene)-4,6-androstadie n-3-one
a) 11.beta.,19-(o-phenylene)-4-androstene-3,17-dione
20 g of the product obtained by the reaction steps in Example 1a), Example 1b) and Example 2a) are separated analogous to the specification in Example 1c) forming 8.69 g of the title compound.
[.alpha.].sub.D.sup.22 =+116.degree. (CHCl.sub.3 ; c=0.51)
Fp.: =284.degree.-288.degree. C.
b) 11.beta.,19-(o-phenylene)-3-ethoxy-3,5-androstadien-17-one
8 g of the product obtained in accordance with a) are placed in a mixture of 85 ml of abs. methylene chloride, 25 ml of ethanol and 6.7 ml of triethyl orthoformate and mixed with 170 mg of p-toluene sulfonic acid (monohydrate) at 0.degree. C. The mixture is subsequently stirred overnight at the temperature of an ice bath, then mixed with a surplus of sodium-hydrogen-carbonate solution and the aqueous phase extracted with methylene chloride. The combined organic phases are washed with a saturated solution of sodium chloride, dried over sodium sulfate and concentrated in vacuo. This yields 11.3 g of impure raw product. Crystallization from ethanol (mixed with a few drops of pyridine) yields 5.43 g of the title compound in crystalline form.
Fp.: =182.degree.-186.degree. C.
[.alpha.].sub.D.sup.22 =+39.degree. (CHCl.sub.3 ; c=0.5)
c) 17-(prop-1-inyl)-11.beta.,19-(o-phenylene)-3-ethoxy-3,5-androstadien-17.be ta.-ol
5 g of the raw product obtained in accordance with b) are converted analgous to Example 2b) to form 5.4 g of the raw product, the purity of which is sufficient for further reactions. Crystallization of 400 mg of the raw product from ethanol yields 268 mg of the title compound in crystalline form.
Fp.: =+203.degree.-207.degree. C.
[.alpha.].sub.D.sup.22 =-91.degree. (CHCl.sub.3 ; c=0.5)
d) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(o-phenylene)-4,6-androstadi en-3-one
5 g of the raw product obtained in accordance with c) are suspended in a mixture of 50 ml of 80% aqueous dioxane solution and 24 ml of 10% aqueous sodium acetate solution. 1.6 g of 1,3-dibromo-5,5-dimethylhydantion are added to this suspension in portions at 0.degree. C., the steroid slowly going into solution. After two hours of reaction the reaction mixture is poured into water and the aqueous phase extracted with methylene chloride. The combined organic phases are washed with a saturated solution of sodium thiosulfate and water, dried over sodium sulfate and concentrated in vacuo.
The impure 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(o-phenylene)-6.beta.-bromo- 4-androsten-3-one thereby obtained is dissolved in 48 ml of abs. dimethylformamide, mixed with 2.4 g of lithium bromide and 1.65 g of lithium carbonate under inert gas and stirred for one hour at 100.degree. C. After the reaction mixture has cooled down to room temperature it is poured into water, the aqueous phase neutralized with 4 n hydrochloric acid, cooled to the temperature of an ice bath, subsequently stirred for one hour at this temperature and the precipitated steroid sucked off. This yields 4.14 g of slightly impure raw product, the purity of which is adequate for further reactions. Starting with 1.14 g of the raw product, crystallization from diisopropyl ether yields 638 mg of the above compound.
[.alpha.].sub.D =+80.degree. (CHCl.sub.3 ; c=0.5)
Fp.: =215.degree.-217.degree. C.
EXAMPLE 4
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-methoxy-o-phenylene)-4-and rosten-3-one
a) 19-(2-chloro-5-methoxyphenyl)-3,3-(2,2-dimethyltrimethylenedioxy)-9(11) -androstene-5.alpha.,17.beta.-diol
Analogous to the specification in Example 1a) 15.5 g of the above compound are obtained when 15 g of 5.alpha.,10.alpha.-epoxy-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-estren- 17.beta.-ol are allowed to react with 2-chloro-5-methoxybenzyl chloride.
b) 11.beta.19-(4-methoxy-o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-and rostane-5.alpha.,17.beta.-diol
Analogous to the specification in Example 1b) 15 g of the compound obtained in accordance with a) yield 11.6 g of the title compound in the form of white foam.
[.alpha.].sub.D.sup.22 =+21.1.degree. (CHCl.sub.3 ; c=0.52)
Fp.: =223.degree.-224.degree. C. (diisopropyl ether)
The title compound b) can also be produced by way of the following synthesis.
.alpha.) 19-(2-bromo-5-methoxyphenyl)-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-and rostene-5.alpha.,17.beta.-diol
150 g of 2-bromo-5-methoxy-benzyl bromide are suspended in 1 liter of abs. diethyl ether under inert gas and mixed with 13.3 g of magnesium chips. After Grignard's reaction has begun the reaction temperature is held beneath 30.degree. C. by cooling. After complete formation of Grignard's reagent 50 g of 5.alpha.,10.alpha.-epoxy-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-estrene -5.alpha.,17.beta.-diol dissolved in 330 ml of abs. tetrahydrofuran are added dropwise while stirring. The reaction mixture is subsequently stirred for 1.5 h and processed as described in Example 1a). After chromatography 66.5 g of the above compound are obtained in the form of white foam.
Fp.: 128.degree.-130.degree. C. (diisopropyl ether/hexane)
.beta.) 11.beta.,19-(4-methoxy-o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-an drostane-5.alpha.,17.beta.-diol
Analogous to Example 1.beta.) 66 g of 19-(2-bromo-5-methoxyphenyl)-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-and rostene-5.alpha.,17.beta.-diol in 1.7 l of absolute toluene are allowed to react with 34 ml of tributyltin hydride by using 660 mg of 2,2-azoisobutyric acid nitrile as the radical starter. After complete reaction the solvent is drawn off in vacuo and the residue crystallized from the diisopropyl ether. This yields 49 g of the above compound in crystalline form.
c) 11.beta.-19-(4-methoxy-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimethyltrim ethylenedioxy)-androstan-17-one
Analogous to Example 2a) 11 g of the compound obtained in accordance with b) are converted into the corresponding keto compound. This yields 9.53 g of the above compound in the form of white foam.
[.alpha.].sub.D.sup.22 =+33.degree. (CHCl.sub.3 ; c=0.55)
Fp.: =235.degree.-238.degree. C.
d) 17-(prop-l-inyl)-11.beta.,19-(4-methoxy-o-phenylene)-3,3-(2,2-dimethyltrim ethylenedioxy)-androstane-5.alpha.,17.beta.-diol
Analogous to Example 2b) 4 g of the compound obtained in accordance with c) are converted into the corresponding 17.alpha.-propinyl compound. After chromatography 3.3 g of the above compound are isolated in the form of white foam.
IR (KBr): 2230 cm.sup.-1 triple bond
e) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-methoxy-o-phenylene)-4-an drosten-3-one
Analogous to Example 1c) 3 g of the compound obtained in accordance with d) are converted into the corresponding 4-ene-keto compound. 1.5 g of the title compound are isolated in the form of white foam.
[.alpha.].sub.D.sup.22 =+18.degree. (CHCl.sub.3 ; c=0.465)
EXAMPLE 5
17-(3-hydroxyprop-1-(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-methoxy-o-phe nylene)-4-androsten-3-one
a) 17-[3-(tetrahydropyran-2-yloxy)-prop-1-inyl]-11.beta.,19-(4-methoxy-o-phen ylene)-3,3-(2,2-dimethyltrimethylenedioxy)-androstane-5.alpha.,17.beta.-dio
28.3 ml of a 15% solution of n-butyllithium in hexane are slowly added dropwise to a solution of 5.7 g of 3-(tetrahydropyran-2-yloxy)-prop-1-ine in 100 ml of abs. tetrahydrofuran under inert gas at 0.degree. C. The mixture is subsequently stirred for 15 minutes at 0.degree. C., and then a solution containing 4 g of the product obtained in accordance with Example 4c) in 60 ml of abs. tetrahydrofuran is added dropwise at 0.degree. to +5.degree. C. The mixture is subsequently stirred for 3 hours at room temperature, then poured into ice water and extracted with acetic ester. After drying of the organic phase over sodium sulfate and concentration in vacuo the raw product is chromatographed over aluminum oxide (neutral, stage III). This yields 4.36 g of the above compound in the form of white foam.
Fp.: =150.degree.-153.degree. C. (diisopropyl ether) [as a 1:1 mixture of epimers as regards the tetrahydropyranyl ether]
b) 17-[3-(terahydropyran-2-yloxy)-prop-1(Z)-enyl]-11.beta.,19-(4-methoxy-o-ph enylene)-3,3-(2,2-dimethyltrimethylenedioxy)-androstane-5.alpha.,17.beta.-d iol
A solution of 4 g of the product obtained in accordance with a) is hydrogenated in 75 ml of tetrahydrofurane after the addition of 5 ml of pyridine and 400 mg of palladium/barium sulfate (10% Pd) at room temperature and normal pressure. When no more water is taken up the mixture is filtered off from the catalyst and the filtrate concentrated. This yields 3.91 g of the above compound in the form of a yellowish foam.
c) 17-[3-hydroxyprop-1(Z)-enyl]-17.beta.-hydroxy-11.beta.,19-(4-methoxy-o-phe nylene)-4-androsten-3-one
Analogous to Example 1c) 3.5 g of the compound obtained in accordance with b) are cleaved. This yields 1.5 g of the title compound in the form of white foam.
[.alpha.].sub.D.sup.22 =+60.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 6
17-(cyanomethyl)-17.beta.-hydroxy-11.beta.,19-(4-methoxy-o-phenylene)-4-and rosten-3-one
a) 11.beta.,19-(4-methoxy-o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-an drostan-[17(.beta.-1')-spiro-3']-oxiran-5.alpha.-ol
1 g of the ketone obtained in accordance with specification 4c) is dissolved in 20 ml of absolute dimethylformamide under inert gas and mixed at 0.degree. C. first with 2.04 g of trimethylsulfonium iodide and then 1.40 g of potassium tert.-butylate. The reaction mixture is subsequently heated slowly to room temperature overnight with constant stirring, then poured into a saturated solution of ammonium chloride and the aqueous phase extracted several times with acetic ester. The combined organic phases are dried over sodium sulfate, concentrated in vacuo and the residue chromatographed over aluminum oxide (neutral, stage III). 895 mg of the above compound are isolated in the form of white foam.
b) 17-cyanomethyl-11.beta.,19-(4-methoxy-o-phenylene)-3,3-(2,2-dimethyltrimet hylenedioxy)-androstane-5.alpha.,17.beta.-diol
850 mg of the epoxide obtained in accordance with a) are disolved in 17 ml of absolute ethanol under inert gas and mixed with a solution of 1.7 g of potassium cyanide in 3.4 ml of water. The reaction mixture is subsequently heated to 50.degree. C. overnight, then poured into ice water and the aqueous phase extracted several times with acetic ester. The combined organic phases are dried over sodium sulfate and concentrated in vacuo until dry. The residue is chromatographed over aluminum oxide (neutral, stage III). 815 mg of the above compound are isolated.
IR (KBr): 2250 cm.sup.-1 C.tbd.N triple bond
c) 17-cyanomethyl-17.beta.-hydroxy-11.beta.,19-(4-methoxy-o-phenylene)-4-andr osten-3-one
800 mg of the compound obtained in accordance with b) are converted into the corresponding 4-ene-3-keto compound analogous to Example 1c). 575 mg of the title compound are isolated.
[.alpha.].sub.D.sup.22 =59.degree. (CHCl.sub.3 ; c=0.505)
Fp.: =155.degree.-156.degree. C. (acetic ester/hexane)
EXAMPLE 7
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-methoxy-o-phenylene)-4,6-a ndrostadien-3-one
a) 11.beta.,19-(4-methoxy-o-phenylene)-4-androstene-3,17-dione
Analogous to Example 1c) 11.2 g of the substance obtained by specification c) in Example 4 are converted to form the corresponding 4-ene-3-keto compound. 7.6 g of the above compound are isolated.
[.alpha.].sub.D.sup.22 =130.degree. (CHCl.sub.3 ; c=0.5)
Fp.: =184.degree.-187.degree. C. (acetic ester)
b) 11.beta.,19-(4-methoxy-o-phenylene)-3-ethoxy-3,5,-androstadien-17-one
Analogous to Example 3b) 5 g of the substance obtained in accordance with a) are allowed to react with ethanol. 2.45 g of the title compound are yielded in crystalline form.
[.alpha.].sub.D.sup.22 =57.degree. (CHCl.sub.3 ; c=0.5)
Fp.: =174.degree.-176.degree. C.
c) 17-(prop-1-inyl)-11.beta.,19-(4-methoxy-o-phenylene)-3-ethoxy-3,5-androsta dien-17.beta.-ol
Analogous to Example 3 c) 2.4 g of the keto compound obtained in accordance with b) are converted. 2.45 g of the raw product are isolated.
[.alpha.].sub.D.sup.22 =-86.degree. (CHCl.sub.3 ; c=0.505)
Fp. =168.degree.-171.degree. C. (ethanol)
d) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-methoxy-o-phenylene)-4,6- androstadien-3-one
Analogous to Example 3d) 2.35 g of the raw product obtained in accordance with c) are converted to form the corresponding 4,6-diene-3-keto compound. Chromatography over silica gel yields 1.43 g of the title compound.
[.alpha.].sub.D.sup.22 =132.degree. (CHCl.sub.3 ; c=0.5)
Fp.: =237.degree.-242.degree. C. (acetic ester)
EXAMPLE 8
17-(3-hydroxyprop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-methylthio-o-p henylene)-4-androsten-3-one
a) 19-(2-chloro-5-methylthiophenyl)-3,3-(2,2-dimethyl-trimethylene-dioxy)-9(1 1)-androstene-5.alpha.,17.beta.-diol
Analogous to Example 1 a), an amount of 34 g of 5.alpha.,10.alpha.-epoxy-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-androst en-17.beta.-ol is allowed to react with 94.5 g of 2-chloro-5-methylthiobenzyl chloride. After chromatography an amount of 43.2 g of the above compound is obtained as white foam.
b) 11.beta.,19-(4-methylthio-o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy) -androstane-5.alpha.,17.beta.-diol
40 g of the substance obtained in accordance with a) is dissolved in 750 ml of absolute tetrahydrofuran and added dropwise at -78.degree. C. to a mixture of 3.79 g of lithium and 3.4 l of liquid ammonia. After 45 minutes of stirring, a mixture of 200 ml of methanol, 200 ml of tetrahydrofuran and 4.6 ml of methyl iodide is added slowly drop by drop at the same temperature. After completion of this addition the mixture is treated in a manner analogous to Example 1b). From the crude product, 18.37 g of the pure title compound is crystallized out.
Fp.: =173.degree.-176.degree. C. (acetic ester)
c) 11.beta.,19-(4-methylthio-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimethylt rimethylenedioxy)-androstan-17-one
Analogous to Example 13c), an amount of 18 g of the compound obtained in accordance with b) is allowed to react with 21.47 g of aluminum triisopropylate and 156 ml of cyclohexanone in 780 ml of absolute toluene to form the corresponding 17-keto compound. After chromatography over aluminum oxide (neutral, stage III), an amount of 13.98 g of the above compound is obtained as white foam.
[.alpha.].sub.D.sup.22 =41.8.degree. (CHCl.sub.3 ; c=0.5)
Fp.=224.degree.-225.degree. C. (acetic ester/hexane)
d) 17-[3-(tetrahydropyran-2-yloxy)-prop-1-inyl]-11.beta.,19-(4-methylthio-o-p henylene)-3,3-(2,2-dimethyltrimethylenedioxy)-androstane-5.alpha.,17.beta.- diol
Analogous to example 5 a), 13.8 g of the substance obtained in accordance with c) is allowed to react with 19 g of 3-(tetra-hydropyran-2-yloxy)-prop-1-ine. After chromatography an amount of 15.65 g of the above compound is isolated as white foam.
IR (KBr): 2230 cm.sup.-1 triple bond
e) 17-[3-(tetrahydropyran-2-yloxy)-prop-1(Z)-enyl]-11.beta.,19-(4-methylthio- o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-androstane-5.alpha.,17.bet a.-diol
Analogous to Example 5 b), 15.5 g of the substance obtained in accordance with d) is hydrogenated with hydrogen using 1.51 g of palladium on barium sulfate (10% Pd), poisoned with 18.9 ml of pyridine, as a catalyst. After chromatography an amount of 14.15 g of the title compound is isolated as white foam.
f) 17-(3-hydroxyprop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-methylthio-o- phenylene)-4-androsten-3-one
5.5 g of the olefin obtained in accordance with e) are allowed to react in a manner similar to Example 1 c with 5 ml of 4 n aqueous hydrochloric acid in 200 ml of acetone to form the 4-ene-3-keto compound. After chromatography over silica gel, an amount of 2.34 g of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =86.degree. (CHCl.sub.3); c=0.51)
Fp.=146.degree.-148.degree. C. (acetic ester/hexane)
EXAMPLE 9
17-(3-hydroxyprop-1(Z)-enyl)-5.alpha.,17.beta.-dihydroxy-11.beta.,19-(4-met hylthio-o-phenylene)-androstan-3-one
a) 17-(3-hydroxyprop-1(Z)-enyl)-5.alpha.,17.beta.-dihydroxy-11.beta.,19-(4-me thylthio-o-phenylene)-androstan-3-one
5 g of the substance obtained in accordance with Example 8 e) is converted in 50 ml of 70% acetic acid at room temperature to the required 3-keto compound. The reaction mixture is subsequently diluted with water and the aqueous phase is extracted with methylene chloride. The united organic phases are washed in sequence with saturated sodium hydrogen sulfate and saturated common salt solution, subsequently being dried over sodium sulfate. After evaporation of the solvents in vacuo, the residue is chromatographed over silica gel and 2.66 g of the above compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =-5.degree. (CHCl.sub.3); c=0.5)
Fp.=193.degree.-195.degree. C. (acetic ester)
EXAMPLE 10
17-(3-hydroxyprop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-methylsulfenyl -o-phenylene)-4-androsten-3-one
a) 17-[3-(tetrahydropyran-2-yloxy)-prop-1(Z)-enyl]-11.beta.,19-(4-methylsulfi nyl-o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-androstane-5.alpha.,17 .beta.-diol
5 g of the substance obtained in accordance with Example 8e) is dissolved in a mixture of 45 ml of tetrahydrofurance, 45 ml of melthanol and 10 ml of water and treated with 5.1 g of sodium periodate. The reaction mixture is stirred overnight at room temperature, filtered over Celite and the filtrate diluted with acetic ester. The organic phase is washed with saturated sodium hydrogen sulfate solution, dried over sodium sulfate and concentrated in vacuo. The residue is chromatographed over aluminum oxide (neutral, stage III). 3.94 g of the above compound is obtained as white foam.
b) 17-(3-hydroxyprop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-methylsulfeny l-o-phenylene)-4-androsten-3-one
Analogous to Example 1 c), 3.8 g pf the substance obtained in accordance with a) is converted to the 4-ene-3-keto compound. After chromatography over silica gel, an amount of 1.66 g of the title compound is isolated.
[.alpha.].sub.D.sup.22 =51.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 11
17-(3-hydroxyprop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-methylthio-o-phen ylene)-4-androsten-3-one
a) 17-(3-hydroxyprop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-methylthio-o-phe nylene)-4-androsten-3-one
Analogous to Example 1 c), 2.5 g of the substance obtained in accordance with Example 8 d) is split to form the corresponding 4-ene-3-keto compound. After chromatography over silica gel, an amount of 1.13 g of the title compound is isolated as white foam.
EXAMPLE 12
17-(3-hydroxyprop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-ethylthio-o-ph enylene)-4-androsten-3-one
a) 11.beta.,19-(4-ethylthio-o-phenylene)-3,3-(2,2-dimethyltrimethyl-enedioxy) -androstance-5.alpha.,17.beta.-diol
Analogous to Example 8b), 10 g of the substance produced in accordance with Example 8a) are allowed to react with 620 mg of lithium and 14.7 ml of ethyl iodide instead of methyliodide. From the crude product, an amount of 4.62 g of the above-mentioned compound is obtained as a crystalline product from acetic ester.vertline.hexane.
[.alpha.].sub.D.sup.22 =39.degree. (CHCl.sub.3 ; c=0.5)
Fp. =164.degree. C.
b) 11.beta.,19-(4-ethylthio-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimethyltr imethylenedioxy)-androstan-17-one
Analogous to Example 13 c), 4.5 g of the substance produced in accordance with a) is converted into the corresponding 17-keto compound. After chromatography, an amount of 3.4 g of the above-mentioned compound is isolated.
[.alpha.].sub.D.sup.22 =44.degree. (CHCl.sub.3 ; c=0.505);
IR (KBr): 1740 cm.sup.-1 pentacyclic ketone
c) 17-[3-(tetrahydropyran-2-yloxy)-prop-1-inyl]-11.beta.,19-(4-ethylthio-o-ph enylene)-3,3-(2,2-dimethyltrimethylenedioxy)-androstane-5.alpha.,17.beta.-d iol
Analogous to Example 5 a), an amount of 3.2 g of the ketone produced in accordance with b) is allowed to react with 4.31 g of 3-(tetrahydropyran-2-yloxy)-prop-1-line. After chromatography, an amount of 3.25 g of the above-mentioned compound is isolated as white foam.
IR (KBr): 2230 cm.sup.-1 triple bond
d) 17-[3-(tetrahydropyran-2-yloxy)-prop-1(Z)-enyl]-11.beta.,19-(4-ethylthio-o -phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-androstane-5.alpha.,17.beta .-diol
Analogous to Example 5b), an amount of 3.1 g of the substance obtained in accordance with c) is hydrogenated with 300 mg of palladium on barium sulfate (10% Pd), poisoned with 3.75 ml of pyridine, as a catalyst. After chromatography, an amount of 2.85 g of the title compound is isolated as white foam.
e) 17-(3-hydroxyprop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-ethylthio-o-p henylene)-4-androsten-3-one
2.7 g of the olefin obtained in accordance with d) is converted in a manner analogous to Example 1 c) with 2.5 ml of 4 n aqueous hydrochloric acid in 100 ml of acetone to the corresponding 4-ene-3-keto compound. After chromatography over silica gel, an amount of 1.35 g of the above compound is isolated as yellowish foam.
[.alpha.].sub.D.sup.22 =85.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 13
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-dimethylamino-o-phenylene) -4-androsten-3-one
a) 19-(2-chloro-5-dimethylaminophenyl)-3,3-(2,2-dimethyltrimethylenedioxy)-9( 11)-androstene-5.alpha.,17.beta.-diol
Analogous to Example 1a), an amount of 14.39 g of the above-mentioned compound was obtained starting from 15 g of 5.alpha.,10.alpha.-epoxy-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-estrene -17.beta.-ol by reaction with 2-chloro-5-dimethylaminobenzyl chloride.
b) 11.beta.,19-(4-dimethylamino-o-phenylene)-3,3-(2,2-dimethyltrimethylenedio xy)-androstane-5.alpha., 17.beta.-diol
Analogous to Example 1 b), an amount of 9.9 g of the above-mentioned compound is obtained as white foam starting from 14 g of the compound obtained in accordance with a).
c) 11.beta.,19-(4-dimethylamino-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimeth yltrimethylenedioxy)-androstan-17-one
11.5 g of the compound produced in accordance with b) is dissolved in 500 ml of toluene and treated in sequence with 13.8 g of aluminum triisopropylate and 100 ml of cyclohexanone. Thereafter the reaction mixture is heated under reflux and approximately one third of the solvent is distilled off. After cooling the mixture is poured into ice water, the emulsion arising is filtered over Celite, the filter residue is washed thoroughly with ethyl acetate, the organic phase of the filtrate is separated and dried over sodium sulfate and concentrated in vacuo. After chromatography of the residue over aluminum oxide (neutral, stage III), an amount of 8.13 g of the title compound is obtained.
Crystallization of 130 mg of this compound from acetic ester yields 67 mg of crystalline 11.beta.,19-(4-dimethylamino-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimeth yltrimethylenedioxy)-androstan-17-one
Fp. =264.degree.-267.degree. C.
[.alpha.].sub.D.sup.22 =28.degree. (CHCl.sub.3 ; c=0.5)
d) 17-(prop-1-inyl)-11.beta.,19-(4-dimethylamino-o-phenylene)-3,3-(2,2-dimeth yltrimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
Analogous to Example 2b), 3 g of the compound obtained in accordance with c) is converted to the corresponding 17.alpha.-propinyl compound. After chromatography, an amount of 2.6 g of the above-mentioned compound is isolated as yellowish foam.
IR (KBr): 2235 cm.sup.-1 triple bond
d) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-dimethylamino-o-phenylene )-4-androsten-3-one
Analogous to Example lc), an amount of 2.5 g of the product obtained in accordance with d) is converted into the corresponding 4-ene-3-keto compound. An amount of 1.58 g of the above-mentioned compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =+28.degree. (CHCl.sub.3 ; c=0.51)
Fp.: =231.degree.-234.degree. C. (ethyl acetate)
The 2-chloro-5-dimethylaminobenzyl chloride required for reaction stage 7a) is produced in the following way:
.alpha.)2-chloro-5-dimethylaminobenzyl chloride
Under an inert atmosphere, 300 g of lithium aluminum hydride is provided in 3 1 of tetrahydrofran at 0.degree. C. and treated in portions with 500 g of 5-amino-2-chlorobenzoic acid nindustrial, 85%). Thereafter the reaction mixture is heated slowly to room temperature and stirred over night at this temperature. For further processing the reaction mixture is cooled to 0.degree. C. and the excessive lithium aluminum hydride is carefuly decomposed with saturated ammonium chloride solution. Thereafter the organic phase is separated from the deposit and this deposit is washed several times with acetic ester and methylene chloride. The united organic phases are washed neutral with saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo. A yield of 242 g of crude 2-chloro-5-aminobenzyl alcohol is obtained the purity of which is adequate for subsequent reactions.
.sup.1 H-NMR (CDCl.sub.3) [.delta.]: 6.3-7.15 (3H, m, aromatic protons); 4.55 (2H, s, benzylic protons)
.beta.) 2-chloro-5-dimethylaminobenzyl alcohol
An amount of 51.8 g of sodium borohydride suspended in a mixture of 30 g of 2-chloro-5-aminobenzyl alcohol and 1 liter of tetrahydrofuran is added dropwise under cooling to a stirred mixture of 235 ml of 2 m sulfuric acid and 88 ml of a 38% solution of formalin in such a way that the temperature remains between -10.degree. C. and 20.degree. C. After completion of this addition, the reaction mixture is made markedly alkaline with solid sodium hydroxide and treated with water. The organic phase is separated off, the aqueous phase extracted several times with methylene chloride and the united organic phases are washed neutral with saturated sodium chloride solution. Thereafter they are dried over sodium sulfate and concentrated in vacuo. A yield of 24 g of 2-chloro-5-dimethylaminobenzyl alcohol is obtained as an oil.
.sup.1 H-NMR (CDCl.sub.3) [.delta.]: 6.4-7.25 (3H, m, aromatic protons); 4.67 (3H, s, benzylic protons); 2.92 (6H, s, protons of the two methyl groups).
.gamma.) 2-chloro-5-dimethylaminobenzyl chloride
23.8 g of N-chlorosuccinimide provided in 600 ml of absolute methylene chloride is cooled to 0.degree. C. and is slowly mixed with 15.6 ml of dimethyl sulfide. Thereafter the suspension thus produced is cooled to -30.degree. C. and carefully mixed with 20 g of 2-chloro-5-dimethylaminobenzyl alcohol. The reaction mixture is then warmed to 0.degree. C. and stirred at this temperature for 3 hours. Thereafter the mixture is diluted with methylene chloride and poured into ice water. The organic phase is separated, washed with saturated sodium chloride solution, dried over sodium sulfate solution and concentrated in vacuo. The residue is chromatographed with hexane over aluminum oxide (neutral, stage III). A yield of 17.2 g of 2-chloro-5-dimethylaminobenzyl chloride is obtained.
.sup.1 H-NMR (CDCl.sub.3) [.delta.]: 6.4-7.3 (3H, m, aromatic protons); 4.61 (2H, s, benzylic protons); 2.92 (6H, s, protons of the two methyl groups).
EXAMPLE 14
17.beta.-hydroxy-17-methoxymethyl-11.beta.,19-(4-dimethylamino-o-phenylene) -4-androsten-3-one
a) 11.beta.,19-(4-dimethylamino-o-phenylene)-3,3-(2,2-dimethyltrimethylenedio xy)-androstane-.vertline.17(.beta.-1')-spiro-3'.vertline.-oxiran-5-ol
2.5 g of the compound prepared in accordance with Example 13 c) is dissolved in an inert atmosphere in 50 ml of abs. dimethyl formamide and cooled to 0.degree. C. This solution is treated in sequence with 5 g of trimethylsulfonium iodide and 3.4 g of potassium tert.-butylate. The reaction mixture is stirred until the reaction is completely finished (DC check). Thereafter the reaction mixture is poured into ice water, the aqueous phase is extracted with acetic ester, the organic phase is washed with sodium chloride solution and dried over sodium sulfate. After evaporation of the solvents, the residue is chromatographed over aluminum oxide (neutral, stage III), an amount of 2.1 g of the above-mentioned compound is isolated as white foam.
b) 17-methoxymethyl-11.beta.,19-(4-dimethylamino-o-phenylene)-3,3-(2,2-dimeth yltrimethylenedioxy)-androstane-5-17.beta.-diol
2 g of the compound prepared in accordance with a) is dissolved in 40 ml of 3 m methanolic sodium methylate solution and then heated under reflux in an inert atmosphere for 5 hours. After cooling, the reaction mixture is poured into ice water, the aqueous phase is extracted with methylene chloride and the organic phase is washed with sodium chloride solution. After drying of the organic phase over sodium sulfate, concentration in vacuo and chromatography of the residue over aluminum hydroxide (neutral, stage III), an amount of 1.41 g of the above-mentioned compound is isolated as white foam.
c) 17.beta.-hydroxy-17-methoxymethyl-11.beta.,19-(4-dimethylamino-o-phenylene )-4-androsten-3-one
Analogous to Example 1c), 1.3 g of the product obtained in accordance with b) is converted to the corresponding 4-ene-3-keto compound. An amount of 0.75 g of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =80.degree. (CHCl.sub.3 ; c=0.505)
Fp.=124.degree.-127.degree. C.
EXAMPLE 15
17-cyanomethyl-17.beta.-hydroxy-11.beta.,19-(4-dimethylamino-o-phenylene)-4 -androsten-3-one
a) 17-cyanomethyl-11.beta.,19-(4-dimethylamino-o-phenylene)-3,3-(2,2-dimethyl trimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
Analogous to Example 6 b), 2.2 g of the epoxide prepared in accordance with Example 14 a) is allowed to react in 42 ml of ethanol with a solution of 4.22 g of potassium cyanide in 8.4 ml of water. After chromatography, an amount of 1.95 g of the above-mentioned compound is isolated.
IR (KBr): 2245 cm.sup.-1 C.dbd.N triple bond
b) 17-cyanomethyl-17.beta.-hydroxy-11.beta.,19-(4-dimethylamino-o-phenylene)- 4-androsten-3-one
Analogous to Example 1 c), an amount of 1.9 g of the cyanide obtained in accordance with a) is converted into the corresponding 4-ene-3-keto compound. From the crude product an amount of 1.23 g of the title compound is crystallized directly. Chromatography of the mother liquor leads to a further 138 mg of the required cyano compound.
[.alpha.].sub.D.sup.22 =77.degree. (CHCl.sub.3 ; c=0.5)
Fp.=172.degree.-176.degree. C.
EXAMPLE 16
17-(3-hydroxyprop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-dimethylamino-o-p henylene)-4-androsten-3-one
a) 17-[3-(tetrahydropyran-2-yloxy)-prop-1-inyl]-11.beta.,19-(4-dimethylamino- o-phenylene)-3,3-(2,2-dimethyl-trimethylene dioxy)-androstane-5.alpha.-17.beta.-diol
Analogous to Example 5 a), 10 g of the keto compound prepared in accordance with Example 13 c) is allowed to react with 55.3 g of 3-(tetrahydropyran-2-yloxy)-propine and 247 ml of a 15% solution of n-butyllithium in hexane. After chromatography 11.74 g of the above-mentioned compound is obtained as white foam.
IR (KBr): 2230 cm.sup.-1 triple bond
b) 17-(3-hydroxyprop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-dimethylamino-o- phenylene)-4-androsten-3-one
Analogous to Example 1 c), 11.74 g of the compound prepared in accordance with a) is converted into 6.97 g of the title compound.
[.alpha.].sub.D.sup.22 =25.6.degree. (CHCl.sub.3 ; c=0.5)
Fp.=251.degree.-253.degree. C. (acetic ester)
EXAMPLE 17
17-(3-hydroxyprop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-dimethylamino- o-phenylene)-4-androsten-3-one
a) 17-(3-hydroxyprop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-dimethylamino -o-phenylene)-4-androsten-3-one
Analogous to Example 5 b), an amount of 6.5 g of the acetylene compound prepared in accordance with Example 16 b) is converted to the corresponding Z-olefin. After chromatography over silica gel, an amount of 4.76 g of the above-mentioned title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =71.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 18
17.beta.-hydroxy-11.beta.,19-(4-hydroxy-o-phenylene)-4-androsten-3-one
a) 11.beta.,19-(4-hydroxy-o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-an drostane-5.alpha.,17.beta.-diol
50 g of the methoxy compound obtained in a manner analogous to Example 4 .beta.) is dissolved in 500 ml of absolute dimethyl formamide and then treated under an inert gas atmosphere with 28.2 g of sodium methanethiolate. Under this inert gas the reaction mixture is heated under reflux for 3 hours, cooled to room temperature and then poured into 8 l of ice water. The mixture is then stirred at room temperature until the crude product has precipitated as a solid substance. The product is then sucked off, washed with water and dried in vacuo. An amount of 49.2 g of the crude title compound is isolated as a white solid the quality of which is adequate for further reactions.
[.alpha.].sub.D.sup.22 =21.degree. (CHCl.sub.3 ; c=0.5)
Fp.=267.degree.-270.degree. C. (acetic ester)
b) 17.beta.-hydroxy-11.beta.,19-(4-hydroxy-o-phenylene)-4-androsten-3-one
2 g of the phenol obtained in accordance with a) is converted into the 4-ene-3-keto compound in a manner analogous to Example 1 c) with 3 ml of 4 n aqueous hydrochloric acid in 60 ml of acetone. An amount of 1.05 g of the above-mentioned compound is isolated as white foam.
Fp.=242.degree.-245.degree. C. (acetic ester)
EXAMPLE 19
17.beta.-hydroxy-11.beta.,19-(4-trifluoromethyl-sulfonyloxy-o-phenylene)-4- androsten-3-one
a) 17.beta.-hydroxy-11.beta.,19-(4-trifluoro-methyl-sulfonyloxy-o-phenylene)- 4-androsten-3-one
10 g of the phenol prepared in a manner analogous to Example 18 b) is dissolved in 250 ml of absolute methylene chloride and treated with 17.3 g of 4-dimethylamino-pyridine. In an inert atmosphere, the solution is then cooled to -50.degree. C. and treated by slowly adding dropwise 4.76 ml of trifluoromethane sulfonic acid anhydride dissolved in 30 ml of absolute methylene chloride. After 15 minutes of stirring at -50.degree. C. the reaction mixture is poured into saturated sodium bicarbonate solution and the aqueous phase is extracted with methylene chloride. The united organic phases are washed with saturated sodium chloride solution, dried over sodium sulfate and concentrated under a vacuum. After chromatography of the residue over silica gel, an amount of 11.37 g of the title compound is obtained as yellowish foam.
Fp.=204.degree.-205.degree. C. (diisopropyl ether)
EXAMPLE 20
17.beta.-hydroxy-11.beta.,19-[4-(2-trimethyl-silyl-ethinyl)-o-phenylene]-4- androsten-3-one
a) 17.beta.-hydroxy-11.beta.,19-[4-(2-trimethyl-silyl-ethinyl)-o-phenylene]-4 -androsten-3-one
1 g of the triflate compound prepared in accordance with Example 19 a) is dissolved in 10 ml of absolute dimethyl formamide and treated under inert gas with triethylamine, 1.39 ml of trimethylsilyl acetylene and 49 mg of palladium tetrakistriphenyl phosphine. Thereafter the reaction mixture is heated for 1 hour at 110.degree. C., then cooled to room temperature and diluted with acetic ester. After filtration over Celite, the filtrate is washed several times with saturated sodium chloride solution, the organic phase separated, dried over sodium sulfate and concentrated in vacuo. Chromatography of the residue over silica gel yields 656 mg of the title compound as white foam.
Fp.=267.degree.-271.degree. C. (diisopropyl ether)
EXAMPLE 21
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(2-trimethylsilylethinyl)- o-phenylene]-4-androsten-3-one
a) 11.beta.,19-(4-trifluoromethyl-sulfonyloxy-o-phenylene)-3,3-(2,2-dimethylt rimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
40 g of the phenol prepared in accordance with Example 18a) is allowed to react with 14.93 ml of trifluoromethane sulfonic acid anhydride analogous to Example 19a). After chromatography, 37.3 g of the above compound is isolated as white foam.
b) 11.beta.,19-[4-(2-trimethylsilylethinyl)-o-phenylene]-3,3-(2,2-dimethyltri methylenedioxy)-androstane-5.alpha.,17.beta.-diol
15 g of the compound prepared in accordance with Example 20a) is allowed to react with 17.3 ml of trimethylsilyl acetylene. After chromatography over aluminum oxide (neutral, stage III), an amount of 11.7 g of the above compound is isolated as white foam.
IR (KBr): 2150 cm.sup.-1 triple bond in the aromate
c) 11.beta.,19-[4-(trimethylsilylethinyl)-o-phenylene]-5.alpha.-hydroxy-3,3-( 2,2-dimethyltrimethylenedioxy)-androstan-17-one
11.2 g of the substance obtained in accordance with b) is oxidized in a manner analogous to Example 2 a) to the corresponding 17-keto compound with 11.69 g of chromium trioxide. Chromatography over aluminum oxide (neutral, stage III) yields 9.05 g of the above compound as white foam.
[.alpha.].sub.D.sup.22 =51.degree. (CHCl.sub.3 ; c=0.5)
Fp=245.degree.-248.degree. C. (diisopropyl ether)
d) 17-(prop-1-inyl)-11.beta.,19-[4-(2-trimethylsilylethinyl)-o-phenylene]-3,3 -(2,2-dimethyltrimethylene-dioxy)-androstane-5.alpha.,17.beta.-diol
1 g of the ketone prepared in accordance with c) is treated with propine in a manner analogous to Example 2b). After chromatography over aluminum oxide (neutral, stage III), an amount of 956 mg is isolated as white foam.
IR (KBr): 2250 cm.sup.-1 triple bond on the aromate 2235 cm.sup.-1 triple bond
e) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(2-trimethylsilylethinyl) -o-phenylene]-4-androsten-3-one
900 mg of the compound produced in accordance with d) is split analogous to Example 1 c) to form the corresponding 4-ene-3-keto compound. After chromatography over silica gel, an amount of 471 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =59.degree. (CHCl.sub.3 ; c=0.505)
EXAMPLE 22
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-ethinyl-o-phenylene)-4-and rosten-3-one
a) 11.beta.,19-(4-ethinyl-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimethyltrim ethylenedioxy)-androstan-17-one
1.5 g of the ketone produced in accordance with Example 21 c) is dissolved in 26 ml of absolute methanol and mixed with 1.1 g of water-free potassium carbonate. In an inert atmosphere the reaction mixture is stirred for 3 hours, then poured into saturated sodium chloride solution, the aqueous phase being extracted several times with methylene chloride. The united organic phases are washed with saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo. The quality of the crude product (1.31 g) is adequate for further reactions. Chromatography of 100 mg of the crude product over aluminum oxide (neutral, stage III) yields 67 mg of the pure title compound as white foam.
b) 17-(prop-1-inyl)-11.beta.,19-(4-ethinyl-o-phenylene)-3,3-(2,2-dimethyltrim ethylenedioxy)-androstane-5.alpha.,17.beta.-diol
1.2 g of the product obtained in accordance with a) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 1.12 g of the above-mentioned compound is isolated as white foam.
IR (KBr): 2110 cm.sup.-1 triple bond on the aromate 2235 cm.sup.-1 triple bond
c) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-ethinyl-o-phenylene)-4-an drosten-3-one
1.1 g of the substance prepared in accordance with b) is converted to the corresponding 4-ene-3-keto compound analogous to Example 1 c). After chromatography over silica gel, an amount of 612 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =41.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 23
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(2-trimethylsilylethyl)-o- phenylene]-4-androsten-3-one
a) 11.beta.,19-[4-(2-trimethyl-silyl-ethyl)-o-phenylene]-5.alpha.-hydroxy-3,3 -(2,2-dimethyltrimethylenedioxy)-androstan-17-one
1 g of the ketone prepared in accordance with Example 21 c) is dissolved in 10 ml of absolute ethanol and hydrogenated at normal pressure with 100 mg of palladium on carbon (10%) as a catalyst. After absorption of 2 equivalents of hydrogen, the reaction mixture is filtered under suction over Celite. The filter residue is washed with acetic ester and the filtrate is concentrated in vacuo. After chromatography of the residue over aluminum oxide (neutral, stage III), an amount of 884 mg of the above compound is isolated as white foam.
b) 17-(prop-1-inyl)-11.beta.,19-[4-(2-trimethylsilylethyl)-o-phenylene]-3,3-( 2,2-dimethyltrimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
850 mg of the ketone prepared in accordance with a) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 845 mg of the above-mentioned compound is isolated as white foam.
IR (KBr): 2235 cm.sup.-1 triple bond
c) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(2-trimethylsilylethyl)-o -phenylene]-4-androsten-3-one
800 mg of the substance prepared in accordance with b) is converted into the corresponding 4-ene-3-keto compound by a sequence analogous to Example 1 c). After chromatography over silica gel, an amount of 512 mg of the above-mentioned compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =23.degree. (CHCl.sub.3 ; c=0.505)
EXAMPLE 24
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-ethyl-o-phenylene)-4-andro sten-3-one
a) 11.beta.,19-(4-ethyl-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimethyltrimet hylenedioxy)-androstan-17-one
4 g of the acetyl compound obtained in accordance with Example 22 a) is hydrogenated in a manner analogous to Example 23 a) to form the corresponding ethyl compound. After chromatography over aluminum oxide (neutral, stage III), an amount of 3.63 g of the above compound is isolated as white foam.
b) 17-(prop-1-inyl)-11.beta.,19-(4-ethyl-o-phenylene)-3,3-(2,2-dimethyltrimet hylenedioxy)-androstane-5.alpha.,17.beta.-diol
1.5 g of the compound prepared in accordance with a) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 1.43 g of the above-mentioned compound is obtained as white foam.
IR (KBr): 2240 cm.sup.-1 triple bond
c) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-ethyl-o-phenylene)-4-andr osten-3-one
1.3 g of the substance obtained in accordance with b) is converted in a manner analogous to Example 1 c) into the corresponding 4-ene-3-keto compound. After chromatography over silica gel, an amount of 879 mg of the above-mentioned compound is obtained as white foam.
[.alpha.].sub.D.sup.22 =18.degree. (CHCl.sub.3 ; c=0.5)
Fp.=283.degree.-285.degree. C. (acetic ester)
EXAMPLE 25
17-(3-hydroxy-prop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-ethyl-o-pheny lene)-4-androsten-3-one
a) 17-[3-(tetrahydropyran-2-yloxy)-prop-1-inyl]-11.beta.,19-(4-ethyl-o-phenyl ene)-3,3-(2,2-dimethyltrimethelenedioxy)-androstane-5.alpha.,17.beta.-diol
2 g of the ethyl compound prepared in accordance with Example 24 a) is allowed to react in a manner analogous to the specifications in Example 5 a) with 3-(tetrahydropyrane-2-yloxy)-prop-1-ine. After chromatography over aluminum oxide, an amount of 2.29 g of the title compound is isolated as white foam.
IR (KBr): 2240 cm.sup.-1 triple bond
b) 17-[3-(tetrahydropyran-2-yloxy)-prop-1(Z)-enyl]-11.beta.,19-(4-ethyl-o-phe nylene)-3,3-(2,2-dimethyltrimethelenedioxy)-androstane-5.alpha.,17.beta.-di ol
2.2 g of the acetyl compound obtained in accordance with a) is hydrogenated to the Z-olefin in a manner analogous to Example 5 b). After chromatography (neutral, stage III), an amount of 1.95 g of the title compound is isolated as white foam.
c) 17-(3-hydroxy-prop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-ethyl-o-phen ylene)-4-androsten-3-one
1.9 g of the compound prepared in accordance with b) is split to form the corresponding 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 706 mg of the above-mentioned title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =62.degree. (CHCl.sub.3 ; c=0.505)
Fp.=127.degree.-129.degree. C. (acetic ester)
EXAMPLE 26
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-vinyl-o-phenylene)-4-andro sten-3-one
a) 11.beta.,19-(4-hydroxy-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimethyl-tri methylenedioxy)-androstan-17-one
20 g of the 11.beta.,19-(4-methoxy-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimethyltrim ethylenedioxy)-androstan-17-one prepared in accordance with Example 4 c) is converted into the corresponding phenol in a manner analogous to Example 18 a). An amount of 16.8 g of the crude product is isolated, the purity of which is adequate for further reactions. 500 mg of the crude product is chromatographed over aluminum oxide for analytical purposes, yielding 412 mg of the title compound.
b) 11.beta.,19-(4-trifluoromethylsulfonyloxy-o-phenylene)-5.alpha.-hydroxy-3, 3-(2,2-dimethyltrimethylenedioxy)-androstan-17-one
16.3 g of the phenol obtained in accordance with a) is converted into the corresponding trifluorate in a manner analogous to Example 19 a). After chromatography over silica gel, an amount of 15.1 g of the title compound is isolated as white foam.
IR (KBr): 1740 cm.sup.-1 pentacyclic ketone 1215 and 1420 cm.sup.-1 triflate
c) 11.beta.,19-(4-vinyl-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimethyltrimet hylenedioxy)-androstan-17-one
1.5 g of the substance prepared in accordance with b) is dissolved in 18 ml of absolute dimethyl formamide and is then treated with 146 mg of palladium tetrakistriphenyl phosphine and 207 mg of lithium chloride under an inert gas. After stirring for 5 minutes, the reaction mixture is treated with 0.89 ml of tri-n-butylvinyltin and heated to 110.degree. C. After one hour the reaction mixture is cooled to room temperature, diluted with acetic ester and filtered under suction over Celite. The filtrate is washed with saturated sodium chloride, the organic phase is dried over sodium sulfate and concentrated in vacuo. The residue is chromatographed over aluminum oxide (neutral, stage III) yielding an amount of 1.1 g of the title compound as white foam.
d) 17-(prop-1-inyl)-11.beta.,19-(4-vinyl-o-phenylene)-3,3-(2,2-dimethyltrimet hylenedioxy)-androstane-5.alpha.,17.beta.-diol
1 g of the ketone prepared in accordance with a) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 912 mg of the title compound is isolated as white foam.
IR (KBr): 2240 cm.sup.-1 triple bond
e) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-vinyl-o-phenylene)-4-andr osten-3-one
850 g of the compound obtained in accordance with d) is converted into the corresponding 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 485 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =50.degree. (CHCl.sub.3 ; c=0.505)
Fp. =243.degree.-245.degree. C. (diisopropyl ether)
EXAMPLE 27
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(2-propenyl)-o-phenylene]- 4-androsten-3-one
a) 11.beta.,19-[4-(2-propenyl)-o-phenylene]-5.alpha.-hydroxy-3,3-(2,2-dimethy ltrimethylenedioxy)-androstan-17-one
1.5 g of the substance prepared in accordance with Example 26 b) is allowed to react with 0.36 ml of tetraallyl tin in a manner analogous to Example 26 c). After chromatography over silica gel, an amount of 1.06 g of the title compound is isolated as white foam.
b) 17-(prop-1-inyl)-11.beta.,19-[4-(2-propenyl)-o-phenylene]-3,3-(2,2-dimethy ltrimethylenedioxy)-androstan-5.alpha.,17.beta.-one
1 g of the substance obtained in accordance with a) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 942 mg of the title compound is isolated as white foam.
IR (KBr): 2240 cm.sup.-1 triple bond
c) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(2-propenyl)-o-phenylene] -4-androstren-3-one
900 mg of the substance prepared in accordance with b) is converted to the corresponding 4-ene-3-keto compound in a manner analogous to Example 1 c). Chromatography over silica gel yields 397 mg of the title compound as white foam.
[.alpha.].sub.D.sup.22 =18.degree. (CHCl.sub.3 ; c=0.5)
Fp. =275.degree.-277.degree. C. (methylene chloride)
EXAMPLE 28
17.beta.-hydroxy-11.beta.,19-(4-acetyl-o-phenylene)-4-androsten-3-one
a) 11.beta.,19-(4-acetyl-o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-and rostane-5.alpha.,17.beta.-diol
30 g of the trifluroate prepared in accordance with Example 21 a) is treated with 22.06 g of 1-ethoxy-vinyl-tributyltin in a manner analogous to Example 26 c). After chromatography over silica gel, an amount of 18.75 g of the title compound is isolated as white foam.
Fp. =179.degree.-181.degree. C. (diisopropyl ether);
[.alpha.].sub.D.sup.22 =146.degree. (CHCl.sub.3 ; c=0.5)
b) 17.beta.-hydroxy-11.beta.,19-(4-acetyl-o-phenylene)-4-androsten-3-one
18 g of the substance obtained in accordance with a) is converted into the corresponding 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 10.8 g of the title compound is isolated as yellowish foam.
Fp. =135.degree.-138.degree. C. (acetic ester/hexane)
EXAMPLE 29
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-acetyl-o-phenylene)-4-andr osten-3-one
a) 11.beta.,19-{4-[1,1-(2,2-dimethyltrimethylenedioxy)-ethyl]-o-phenylene}-3, 3-(2,2-dimethyltrimethylenedioxy)-5-androsten-17.beta.-ol
10 g of the substance obtained in accordance with 28 b) is dissolved in 250 ml of absolute toluene and treated in sequence with 25.7 g of 1,3-dimethylpropanediol and 1.86 g of pyridinium para-toluene sulfonate. The reaction mixture is then heated under reflux for 4 hours and the water arising at the same time is removed azeotropically. The reaction mixture is then cooled to room temperature, poured into ice-cold 5% aqueous sodium hydroxide solution and the aqueous phase is extracted with acetic ester. The united organic phases are washed with saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo. Chromatography of the residue over aluminum oxide (neutral, stage III) yields 10.7 g of the title compound as white foam. b) 11.beta.,19-{4-[1,1-(2,2-dimethyltrimethylenedioxy)-ethyl]-o-phenylene}-3, 3-(2,2-dimethyltrimethylenedioxy)-5-androsten-17-one
10.5 of the substance obtained in accordance with a) is converted into the 17-keto compound in a manner analogous to Example 2 a). An amount of 10.2 g of the crude product is isolated, the purity of which is adequate for further reactions. 500 mg is chromatographed for analytical purposes over aluminum oxide (neutral, stage III) yielding 443 mg of the title compound as white foam.
[.alpha.].sub.D.sup.22 =43.degree. (CHCl.sub.3 ; c=0.5)
Fp. =244.degree.-266.degree. C. (acetic ester)
c) 17-(prop-1-inyl)-11.beta.,19-{4-[1,1-(2,2-dimethyltrimethylenedioxy)-ethyl ]-o-phenylene}-3,3-(2,2-dimethyltrimethylenedioxy)-5-androsten-17.beta.-ol
1.5 g of the crude product obtained in accordance with b) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III) with a mixture of acetic ester/hexane, 1.35 g of the title compound is obtained as white foam.
IR (KBr): 2240 cm.sup.-1 triple bond
d) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-acetyl-o-phenylene)-4-and rosten-3-one
1.3 g of the substance prepared in accordance with c) is split to form the corresponding 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 747 mg of the title compound is isolated as yellowish foam.
[.alpha.].sub.D.sup.22 =36.degree. (CHCl.sub.3 ; c=0.5)
Fp. =186.degree.-187.degree. C. (acetic ester)
EXAMPLE 30
17-(prop-2-inyl)-17.beta.-hydroxy-11.beta.,19-(4-acetyl-o-phenylene)-4-andr osten-3-one
a) 17-(3-trimethylsilylprop-2-inyl)-11.beta.,19-{4-[1,1-(2,2-dimethyltrimethy lenedioxy)-ethyl]-o-phenylene}-3,3-(2,2-dimethyltrimethylenedioxy)-5-andros ten-17.beta.-ol
1.5 g of the compound prepared in accordance with Example 29 b) is allowed to react with 2.3 ml of 1-trimethylsilylprop-1-ine in a manner anaglogous to Example 5 a). After chromatography over aluminum oxide (neutral, stage III), an amount of 1.31 g of the title compound is isolated as white foam.
IR (KBr): 2170 cm.sup.-1 triple bond
b) 17-(prop-2-inyl)-17.beta.-hydroxy-11.beta.,19-(4-acetyl-o-phenylene)-4-and rosten-3-one
1.2 g of the substance prepared in accordance with a) is converted into the corresponding 4-ene-3-keto compound under conditions analogous to those described in Example 1 c). After chromatography over silica gel, 547 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =91.degree. (CHCl.sub.3 ; c=0.5)
Fp. =257.degree.-259.degree. C.
EXAMPLE 31
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-acetyl-o-phenylene)-4,15-a ndrostadien-3-one
a) 11.beta.,19-{4-[1,1-(2,2-dimethyltrimethylenedioxy)-ethyl]-o-phenylene}-3, 3-(2,2-dimethyltrimethylenedioxy)-5,15-androstadien-17-one
1.89 g of the compound prepared in accordance with Example 29 b) dissolved in 20 ml of absolute tetrahydrofuran is added dropwise to a solution of 9.9 mmol of lithium diisopropylamide in 40 ml of absolute tetrahydrofuran in an inert atmosphere at 0.degree. C. Thereupon chlorotrimethylsilane (2.39 ml) is added dropwise to the reaction mixture. After having been stirred for 30 minutes the reaction solution is poured into ice-cold saturated sodium bicarbonate solution, the aqueous phase then being extracted with acetic ester and the organic phase being washed with water and saturated ammonium chloride solution. After drying over sodium sulfate, the organic phase is concentrated in vacuo. An amount of 1.96 g of 17-trimethylsilyloxy-11.beta.,19-{4-[1,1-(2,2-dimethyltrimethylenedioxy )-ethyl]-o-phenylene}-3,3-(2,2-dimethyltrimethylenedioxy)-5,16-androstadien e is isolated in a crude state as yellowish foam. This crude product is suspended in 23 ml of absolute acetonitrile and treated with 1 g of palladium (II) acetate. After having been stirred for two hours at room temperature, the reaction mixture is filtered under suction over Celite, the filter residue washed with acetic ester and the filtrate is concentrated under in vacuo. The residue is chromatographed over aluminum oxide (neutral, stage III), an amount of 1.33 g of the title compound being obtained as white foam.
IR (KBr): 1710 cm.sup.-1 unsaturated pentacyclic ketone
b) 17-(prop-1-inyl)-11.beta.,19-{4-[1,1-(2,2-dimethyltrimethylenedioxy)-ethyl ]-o-phenylene}-3,3-(2,2-dimethyltrimethylenedioxy)-5,15-androstadien-17.bet a.-ol
1.3 g of the substance prepared in accordance with a) are allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 1.23 g of the title compound is isolated as white foam.
IR (KBr): 2230 cm.sup.-1 triple bond
c) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-acetyl-o-phenylene)-4,15- androstadien-3-one
1.1 g of the substance prepared in accordance with b) is split to form the corresponding 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 617 mg of the title compound is isolated as yellowish foam.
[.alpha.].sub.D.sup.22 =114.degree. (CHCl.sub.3 ; c=0.5)
Fp. =189.degree.-191.degree. C. (acetic ester)
EXAMPLE 32
17-methoxymethyl-17.beta.-hydroxy-11.beta.,19-(4-acetyl-o-phenylene)-4-andr osten-3-one
a) 11.beta.,19-{4-[1,1-(2,2-dimethyltrimethylenedioxy)-ethyl]-o-phenylene}-3, 3-(2,2-dimethyltrimethylenedioxy)-5-androsten-[17(.beta.-1')-spiro-3']-oxir ane
4 g of the compound prepared in accordance with Example 29 b) is allowed to react with 7.13 g of trimethylsulfonium iodide in a manner analogous to Example 14 a). After chromatography over aluminum oxide (neutral, stage III), an amount of 3.76 g of the title compound is isolated as white foam.
b) 17-methoxymethyl-11.beta.,19-{4-[1,1-(2,2-dimethyltrimethylenedioxy)-ethyl ]-o-phenylene}-3,3-(2,2-dimethyltrimethylenedioxy)-5-androsten-17.beta.-ol
1.8 g of the substance prepared in accordance with a) is allowed to react with sodium methylate in a manner analogous to Example 14 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 1.55 g of the title compound is isolated as white foam.
c) 17-methoxymethyl-17.beta.-hydroxy-11.beta.,19-(4-acetyl-o-phenylene)-4-and rosten-3-one
1.5 g of the substance obtained in accordance with b) is split to form the corresponding 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 561 mg of the title compound is isolated as yellowish foam.
[.alpha.].sub.D.sup.22 =76.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 33
17-cyanomethyl-17.beta.-hydroxy-11.beta.,19-(4-acetyl-o-phenylene)-4-andros ten-3-one
a) 17-cyanomethyl-11.beta.,19-{4-[1,1-(2,2-dimethyltrimethylenedioxy)-ethyl]- o-phenylene}-3,3-(2,2-dimethyltrimethylenedioxy)-5-androsten-17.beta.-ol
1.8 g of the substance obtained in accordance with Example 32 a) is allowed to react with potassium cyanide in a manner analogous to Example 6 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 1.67 g of the title compound is isolated as white foam.
IR (KBr): 2250 cm.sup.-1 C.tbd.N triple bond
b) 17-cyanomethyl-17.beta.-hydroxy-11.beta.,19-(4-acetyl-o-phenylene)-4-andro sten-3-one
1.5 g of the substance obtained in accordance with a) is split to form the corresponding 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 732 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =83.degree. (CHCl.sub.3 ; c=0.5)
Fp.=184.degree.-185.degree. C. (methylene chloride)
EXAMPLE 34
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-isopropenyl-o-phenylene)-4 -androsten-3-one
a) 11.beta.,19-(4-isopropenyl-o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy )-androstane-5.alpha.,17.beta.-diol
In an inert atmosphere, 1.94 g of sodium hydride is warmed at 70.degree. C. in 20 ml of absolute dimethyl sulfoxide until no more gas production is detected. The solution is then cooled down to 0.degree. C. and treated dropwise with methyltriphenyl phosphonium bromide dissolved in 61 ml of absolute dimethyl sulfoxide. After stirring at room temperature, 10.3 g of the compound prepared in accordance with Example 28 a) dissolved in 10 ml of absolute dimethyl sulfoxide is added dropwise, the reaction mixture being stirred for 3 hours. Thereafter the reaction mixture is poured into cold saturated sodium bicarbonate solution. The aqueous phase is extracted with acetic ester and the organic phases are washed with saturated sodium chloride solution. The united organic phases are dried over sodium sulfate and concentrated in vacuo. The residue is chromatographed over aluminum oxide (neutral, stage III). This yields 8.3 g of the title compound as white foam.
Fp.=155.degree.-157.degree. C. (diisopropyl ether)
b) 11.beta.,19-(4-isopropenyl-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimethyl trimethylenedioxy)-androstan-17-one
8.1 g of the substance prepared in accordance with a) is oxidized with chromium trioxide in a manner analogous to Example 2 a). After chromatography over aluminum oxide (neutral, stage III), an amount of 7.8 g of the title compound is isolated as white foam.
Fp.=238.degree.-240.degree. C. (diisopropyl ether)
c) 17-(prop-1-inyl)-11.beta.,19-(4-isopropenyl-o-phenylene)-3,3-(2,2-dimethyl trimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
1.5 g of the substance obtained in accordance with b) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 1.34 g of the title compound is isolated as white foam.
IR (KBr): 2240 cm.sup.-1 triple bond d) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-isopropenyl-o-phenylene)- 4-androsten-3-one
1.3 g of the compound obtained in accordance with c) is converted to the 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 706 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =41.degree. (CHCl.sub.3 ; c=0.5)
Fp.=247.degree.-250.degree. C. (diisopropyl ether)
As a by-product 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(1-methyl-hydroxyethyl)-o -phenylene]-4-androsten-3-one (354 mg) is isolated as white foam.
[.alpha.].sub.D.sup.22 =17.degree. (CHCl.sub.3 ; c=0.5)
Fp.=222.degree.-224.degree. C.
EXAMPLE 35
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-isopropyl-o-phenylene)-4-a ndrosten-3-one
a) 11.beta.,19-(4-isopropyl-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dimethyltr imethylenedioxy)-androstan-17-one
2 g of the substance obtained in accordance with Example 34 b) is hydrogenated as described in Example 23 a) but only up to absorption of one equivalent of hydrogen, with palladium as a catalyst. After chromatography over aluminum oxide (neutral, stage III), an amount of 1.83 g of the title compound is isolated as white foam.
b) 17-(prop-1-inyl)-11.beta.,19-(4-isopropenyl-o-phenylene)-3,3-(2,2-dimethyl trimethylenedioxy)-androstene-5.alpha.,17.beta.-diol
1.8 g of the substance prepared in accordance with a) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 1.81 g of the title compound is isolated as white foam.
c) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-isopropenyl-o-phenylene)- 4-androsten-3-one
1.7 g of the substance prepared in accordance with b) is split to form the 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 932 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =21.degree. (CHCl.sub.3 ; c=0.505)
Fp.=240.degree.-243.degree. C. (acetic ester)
EXAMPLE 36
17-(3-hydroxyprop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-isopropenyl-o- phenylene)-4-androsten-3-one
a) 17-[3-(tetrahydropyran-2-yloxy)-prop-1-inyl]-11.beta.,19-(4-isopropenyl-o- phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-androstane-5.alpha.,17.beta. -diol
2 g of the substance obtained in accordance with Example 34 b) is allowed to react with 3-(tetrahydropyran-2-yloxy)-prop-1-ine in a manner analogous to Example 5 a). After chromatography over aluminum oxide (neutral, stage III), an amount of 2.1 g of the title compound is isolated as white foam.
b) 17-[3-(tetrahydropyran-2-yloxy)-prop-1(Z)-enyl]-11.beta.,19-(4-isopropenyl -o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-androstane-5.alpha.,17.be ta.-diol
2 g of the compound obtained in accordance with a) is hydrogenated in a manner analogous to Example 5 b) with Lindlar's catalyst. After chromatography over aluminum oxide (neutral, stage III), an amount of 1.78 g of the title compound is isolated as white foam. c) 17-(3-hydroxyprop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-isopropenyl-o -phenylene)-4-androsten-3-one
1.7 g of the compound obtained in accordance with b) is split to form the 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 567 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =79.degree. (CHCl.sub.3 ; c=0.5)
Fp.=143.degree.-145.degree. C. (acetic ester)
As a by-product 178 mg of 17-(3-hydroxyprop-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-[4-(1-methyl-1-h ydroxyethyl)-o-phenylene]-4-androstene-3-one is isolated as white foam.
[.alpha.].sub.D.sup.22 =61.degree. (CHCl.sub.3 ; c=0.5)
Fp.=208.degree.-211.degree. C. (acetic ester)
EXAMPLE 37
17-(4-hydroxybut-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-isopropenyl-o-p henylene)-4-androsten-3-one
a) 17-(4-hydroxybut-1-inyl)-11.beta.,19-(4-isopropenyl-o-phenylene)-3,3-(2,2- dimethyltrimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
2 g of the substance obtained in accordance with Example 34 b) is dissolved in 60 ml of absolute tetrahydrofuran and is treated in sequence in an inert atmosphere with 2.27 ml n-but-1-in-4-ol and 4.09 g of potassium methylate. During this process of addition and the subsequent 14 hour period of stirring the reaction mixture is kept at 0.degree. C. Thereafter it is poured into water and the aqueous phase is extracted with acetic ester. The united organic phases are washed with saturated sodium chloride solution, dried over sodium sulfate and concentrated in vacuo. The residue is chromatographed over aluminum oxide (neutral, stage III) and an amount of 1.2 g of the title compound is isolated as white foam.
IR (KBr): 2240 cm.sup.-1 triple bond
b) 17-(4-hydroxybut-1(Z)-enyl)-11.beta.,19-(4-isopropenyl-o-phenylene)-3,3-(2 ,2-dimethyltrimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
1 g of the substance obtained in accordance with a) is hydrogenated using Lindlar's catalyst in a manner analogous to Example 5 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 836 mg of the title compound is obtained as white foam.
c) 17-(4-hydroxybut-1(Z)-enyl)-17.beta.-hydroxy-11.beta.,19-(4-isopropenyl-o- phenylene)-4-androsten-3-one
800 mg of the substance obtained in accordance with b) is split to form the 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 306 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =78.degree. (CHCl.sub.3 ; c=0.515)
EXAMPLE 38
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-diethoxyphosphoryl-o-pheny lene)-4-androsten-3-one
a) 11.beta.,19-(4-diethoxyphosphoryl-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-d imethyltrimethylenedioxy)-androstan-17-one
1.5 g of the trifluorate obtained in accordance with Example 26 b) is dissolved in 10 ml of absolute triethylamine and treated in an inert atmosphere with 122 mg of tetrakistriphenyl phosphine palladium and 0.46 ml of phosphorous acid diethyl ester. Thereafter the reaction mixture is heated for 1.5 hours under reflux. After addition of a further 100 mg of tetrakistriphenyl phosphine palladium and 0.46 ml of phosphorous acid diethyl ester, the reaction mixture is heated under reflux for a further 1.5 hours, allowed to cool to room temperature and concentrated in vacuo. The residue is chromatographed over silica gel and yields 1.05 g of the title compound as white foam.
b) 17-(prop-1-inyl)-11.beta.,19-(4-diethoxyphosphoryl-o-phenylene)-3,3-(2,2-d imethyltrimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
1 g of the substance prepared in accordance with a) is allowed to react with propine in a manner analogous to Example 2 b). Chromatography over aluminum oxide (neutral, stage III) yields 832 mg of the title compound as white foam.
IR (KBr): 2240 cm.sup.-1 triple bond
c) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4-diethoxyphosphoryl-o-phen ylene)-4-androsten-3-one
800 mg of the substance prepared in accordance with b) is split to form the 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 440 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =17.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 39
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(2-thienyl)-o-phenylene]-4 -androsten-3-one
a) 11.beta.,19-[4-(2-thienyl)-o-phenylene]-3,3-(2,2-dimethyltrimethylenedioxy )-androstane-5.alpha.,17.beta.-diol
1.26 g of the substance prepared in accordance with Example 21 a) is dissolved in 36 ml of absolute dioxane and treated in an inert atmosphere with 3.04 ml of hexa-n-butyl-di-tin, 254 mg of lithium chloride and 100 mg of tetrakistriphenyl phosphine palladium. Thereupon the reaction mixture is heated to 110.degree. C. and kept at this temperature for 1 hour before addition of 1.94 ml of 2-bromothiophene. It is then stirred for a further period of 18 hours at 110.degree. C. The reaction mixture is then cooled to room temperature and filtered over Celite. After concentration of the filtrate, the residue is chromatographed over silica gel to yield 545 mg of the title compound as yellowish foam.
As an example of this type of coupling the following tin compound was isolated.
.alpha.) 11.beta.,19-(4-tri-n-butylstannyl-o-phenylene)-3,3-(2,2-dimethyltrimethyle nedioxy)-androstane-5.alpha.,17.beta.-diol
1.26 g of the substance prepared in accordance with Example 21 a) is allowed to react with 3.04 ml of hexa-n-butyl-di-tin under conditions analogous to those described under a). After heating for 1 hour at 110.degree. C., the reaction mixture is treated further in a normal manner. Chromatography over silica gel yields 625 mg of the title compound as white foam.
[.alpha.].sub.D.sup.22 =25.degree. (CHCl.sub.3 ; c=0.5)
Fp.=137.degree.-139.degree. C. (diisopropyl ether)
b) 11.beta.,19-[4-(2-thienyl)-o-phenylene]-5.alpha.-hydroxy-3,3-(2,2-dimethyl trimethylenedioxy)-androstan-17-one
400 mg of N-chlorosuccinimide is provided in 5 ml of absolute methylene chloride at 0.degree. C. After dropwise addition of 0.3 ml of dimethyl sulfide, the mixture is stirred for 30 minutes at 0.degree. C. Thereupon 510 mg of the substance obtained in accordance with a) dissolved in 5 ml of absolute methylene chloride is slowly added drop for drop. After two hours of stirring with exclusion of moisture, 0.6 ml of triethylamine is added dropwise to the reaction mixture. This is then poured into water, the aqueous phase is extracted with methylene chloride and the organic phase is washed with saturated sodium chloride solution. Thereafter it is dried over sodium sulfate and concentrated in vacuo. After chromatography of the residue over aluminum oxide (neutral, stage III), an amount of 387 mg of the title compound is isolated as yellowish foam.
IR (KBr): 1740 cm.sup.-1 pentacyclic ketone
c) 17-(prop-1-inyl)-11.beta.,19-[4-(2-thienyl)-o-phenylene]-3,3-(2,2-dimethyl trimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
350 mg of the substance obtained in accordance with b) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 343 mg of the title compound is isolated as yellowish foam.
IR (KBr): 2240 cm.sup.-1 triple bond
d) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(2-thienyl)-o-phenyl-ene] -4-androsten-3-one
320 mg of the compound obtained in accordance with d) is split to form the 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 234 mg of the title compound is isolated as yellowish foam.
[.alpha.]=65.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 40
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(3-thienyl)-o-phenylene]-4 -androsten-3-one
a) 11.beta.,19-[4-(3-thienyl)-o-phenylene]-5.alpha.-hydroxy-3,3-(2,2-dimethyl trimethylenedioxy)-androstan-17-one
1.26 g of the substance obtained in accordance with Example 26 b) is allowed to react with 2 ml of 3-bromothiophene under conditions analogous to those described under Example 39 a). After chromatography over aluminum oxide (neutral, stage III), an amount of 546 mg is isolated as yellowish foam.
b) 17-(prop-1-inyl)-11.beta.,19-[4-(3-thienyl)-o-phenylene]-3,3-(2,2-dimethyl trimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
520 mg of the substance prepared in accordance with a) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 462 mg of the title compound is isolated as yellowish foam.
IR (KBr): 2250 cm.sup.-1 triple bond
c) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(3-thienyl)-o-phenyl-ene] -4-androsten-3-one
410 mg of the substance obtained in accordance with b) is split to form the 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 287 mg of the title compound is isolated as yellowish foam.
[.alpha.].sub.D.sup.22 =61.degree. (CHCl.sub.3 ; c=0.51)
EXAMPLE 41
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(3-furyl)-o-phenylene]-4-a ndrosten-3-one
a) 11.beta.,19-[4-(3-furyl)-o-phenylene]-5.alpha.-hydroxy-3,3-(2,2-dimethyltr imethylenedioxy)-androstan-17-one
1.26 g of the substance prepared in accordance with Example 26 b) is allowed to react with 1.8 ml of 3-bromofuran in a manner analogous to Example 39 a). After chromatography over silica gel, an amount of 660 mg of the title compound is isolated as white foam.
Fp.=240.degree.-243.degree. C. (acetic ester)
b) 17-(prop-1-inyl)-11.beta.,19-[4-(3-furyl)-o-phenylene]-3,3-(2,2-dimethyltr imethylenedioxy)-androstane-5.alpha.-17.beta.-diol
630 mg of the substance obtained in accordance with a) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 615 mg of the title compound is isolated as white foam.
IR (KBr): 2240 cm.sup.-1 triple bond
c) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(3-furyl)-o-phenylene]-4- androsten-3-one
590 mg of the substance obtained in accordance with b) is allowed to react to form the 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 289 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =49.degree. (CHCl.sub.3 ; c=0.51)
EXAMPLE 42
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(3-methoxyphenyl)-o-phenyl ene]-4-androsten-3-one
a) 11.beta.,19-[4-(3-methoxyphenyl)-o-phenylene]-5.alpha.-hydroxy-3,3-(2,2-di methyltrimethylenedioxy)-androstan-17-one
1.26 g of the substance prepared in accordance with Example 26 b) is allowed to react with 2.53 ml of 3-bromo-anisol in a manner analogous to example 39 a). After chromatography over silica gel, an amount of the 685 mg of the title compound is isolated as white foam.
b) 17-(prop-1-inyl)-11.beta.,19-[4-(3-methoxyphenyl)-o-phenylene]-3,3-(2,2-di methyltrimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
650 mg of the substance prepared in accordance with a) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 635 mg of the title compound is isolated as white foam.
IR (KBr): 2230 cm.sup.-1 triple bond
c) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(3-methoxyphenyl)-o-pheny lene]-4-androsten-3-one
600 mg of the substance prepared in accordance with b) is converted to the 4-ene-3-keto compound under conditions analogous to those described in Example 1 c). After chromatography over silica gel, an amount of 366 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =66.degree. (CHCl.sub.3 ; c=0.5)
Fp.=158.degree.-162.degree. C. (acetic ester/hexane)
EXAMPLE 43
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(4-methoxyphenyl)-o-phenyl ene]-4-androsten-3-one
a) 11.beta.,19-[4-(4-methoxyphenyl)-o-phenylene]-5.alpha.-hydroxy-3,3-(2,2-di methyltrimethylenedioxy)-androstan-17-one
1.26 g of the substance prepared in accordance with Example 26 b) is allowed to react with 2.53 ml of 4-bromo-anisol in a manner analogous to Example 39 a). After chromatography over silica-gel, an amount of 522 mg of the title compound is isolated as white foam.
Fp.=171.degree.-173.degree. C. (acetic ester)
[.alpha.].sub.D.sup.22 =48.degree. (CHCl.sub.3 ; c=0.5)
b) 17-(prop-1-inyl)-11.beta.,19-[4-(4-methoxyphenyl)-o-phenylene]-3,3-(2,2-di methyltrimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
500 mg of the substance prepared in accordance with a) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 498 mg of the title compound is isolated as white foam.
IR (KBr): 2240 cm.sup.-1 triple bond
c) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(4-methoxyphenyl)-o-pheny lene]-4-androsten-3-one
450 mg of the substance prepared in accordance with b) is converted to the 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 276 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =70.degree. (CHCl.sub.3 ; c=0.505)
Fp.=165.degree.-169.degree. C. (acetic ester/hexane)
EXAMPLE 44
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(2-methoxyphenyl)-o-phenyl ene]-4-androsten-3-one
a) 11.beta.,19-[4-(2-methoxyphenyl)-o-phenylene]-5.alpha.-hydroxy-3,3-(2,2-di methyltrimethylenedioxy)-androstan-17-one
1.26 g of the substance obtained in accordance with Example 26 b is allowed to react with 2.53 ml of 2-bromo-anisol in a manner analogous to Example 39 a). After chromatography over silica gel, an amount of 448 mg of the title compound is isolated as white foam.
b) 17-(prop-1-inyl)-11.beta.,19-[4-(2-methoxyphenyl)-o-phenylene]-3,3-(2,2-di methyltrimethylenedioxy)-androstane-5.alpha.,17.beta.-diol
410 mg of the substance prepared in accordance with a) is allowed to react with propine in a manner analogous to Example 2 b). After chromatography over aluminum oxide (neutral, stage III), an amount of 405 mg of the title compound is isolated as white foam.
IR (KBr): 2240 cm.sup.-1 triple bond
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-[4-(2-methoxyphenyl)-o-phenyl ene]-4-androsten-3-one
380 mg of the substance prepared in accordance with b) is converted to the 4-ene-3-keto compound in a manner analogous to Example 1 c). After chromatography over silica gel, an amount of 205 mg of the title compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =49.degree. (CHCl.sub.3 ; c=0.51)
EXAMPLE 45
17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4,5-methylenedioxy-o-phenyle ne)-4-androsten-3-one
a) 19-(2-chloro-4,5-methylenedioxyphenyl)-3,3-(2,2-dimethyltrimethylenedioxy) -9(11)-androstene-5.alpha.,17.beta.-diol
Analogous to Example 1 a) 10.3 g of 19-(2-chloro-4,5-methylenedioxyphenyl)-3,3-(2,2-dimethyltrimethylenedioxy) -9(11)-androstene-5.alpha.,17.beta.-diol is obtained from 10 g of 5.alpha.,10.alpha.-epoxy-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-estren- 17.beta.-ol by reaction with 6-chloropiperonyl chloride.
b) 11.beta.,19-(4,5-methylenedioxy-o-phenylene)-3,3-(2,2-dimethyltrimethylene dioxy)-androstane-5.alpha.,17.beta.-diol
Analogous to Example 1 b), an amount of 5.9 g of 11.beta.,19-(4,5-methylenedioxy-o-phenylene)-3,3-(2,2-dimethyltrimethylene dioxy)-androstane-5.alpha.,17.beta.-diol is produced as white foam from 10 g of the compound obtained in accordance with a).
c) 11.beta.,19-(4,5-methylenedioxy-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2-dim ethyltrimethylenedioxy)-androstan-17-one
Analogous to Example 2a) 5.5 g of the compound obtained in accordance with b) is converted into the corresponding keto compound. An amount of 4.2 g of 11.beta.,19-(4,5-methylenedioxy-o-phenylene)-5.alpha.-hydroxy-3,3-(2,2- dimethyltrimethylenedioxy)-androstan-17-one is obtained as white foam.
[.alpha.].sub.D.sup.22 =+45.degree. (CHCl.sub.3 ; c=0.525)
Fp.=219.degree.-222.degree. C. (ethyl acetate)
d) 17-(prop-1-inyl)-11.beta.,19-(4,5-methylenedioxy-o-phenylene)-3,3-(2,2-dim ethyltrimethylenedioxy)-androstane-5.alpha.-17.beta.-diol
Analogous to example 2 b) 4 g of the compound obtained in accordance with c) is converted into the corresponding 17.alpha.-propinyl compound. After chromatography, an amount of 3.5 g of 17-(prop-1-inyl)-11.beta.,19-(4,5-methylenedioxy-o-phenylene)-3,3-(2,2-dim ethyltrimethylenedioxy)-androstane-5.alpha.,17.beta.-diol is isolated as white foam.
IR (KBr): 2230 cm.sup.-1 triple bond
e) 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4,5-methylenedioxy-o-phenyl ene)-4-androsten-3-one
Analogous to Example 1 c) 3 g of the compound obtained in accordance with d) is converted to the corresponding 4-ene-3-keto compound. An amount of 1.36 g of 17-(prop-1-inyl)-17.beta.-hydroxy-11.beta.,19-(4,5-methylenedioxy-o-phenyl ene)-4-androsten-3-one is isolated.
.vertline..alpha..vertline..sub.D.sup.22 =+2.degree. (CHCl.sub.3 ; c=0.485)
EXAMPLE 46
18-Methyl-17-ethinyl-17beta-hydroxy-11beta,19-(4-methoxy-o-phenylene)-4-and rosten-3-one
a) 18-Methyl-5alpha,10alpha-epoxy-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-e stren-17beta-ol
Sodium borohydride (2.38 g) is put in 100 ml of absolute tetrahydrofuran and the suspension is cooled to 0.degree. C. Under protective gas, 20 g of 18-methyl-5alpha,10alpha-epoxy-3,3-(2,2-dimethyltrimethylenedioxy)-9(11)-e stren-17-one (European patent application 0104387A1), dissolved in a mixture of 100 ml of methanol and 100 ml of tetrahydrofuran, is instilled. After 45-minutes additional stirring, saturated sodium bicarbonate solution is slowly instilled to decompose the excess reducing agent, and the aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. The residue is chromatographed on aluminum oxide (neutral, stage III) with a mixture of ethyl acetate/hexane. 18.3 g of the above-mentioned 17beta-hydroxy compound is obtained as white foam.
b) 19-(2-Bromo-5-methoxyphenyl)-18-methyl-3,3-(2,2-dimethyltrimethyenedioxy)- 9(11)-androstene-5alpha,17beta-diol
Analogously to directions described under example 4alpha), 3.8 g of the epoxide prepared under a) is reacted with 16.79 g of 2-bromo-5-methyoxybenzyl bromide. 3.65 g of the above-mentioned compound is obtained as white foam.
c) 18-Methyl-11beta,19-(4-methoxy-o-phenylene)-3,3-(2,2-dimethyltrimethenedio xy)-androstane-5alpha,17beta-diol
3.5 g of the aryl halide prepared under b), dissolved in 100 ml of absolute toluene, is mixed with 46 mg of alpha,alpha-azoisobutyronitrile and then irradiated with an incandescent lamp (300 watts) for 2.5 hours. In this case the irradiation is concentrated by aluminum foil on the reaction vessel and the resulting heat is used for refluxing the reaction mixture. Then the reaction solution is cooled and concentrated by evaporation in a vacuum. The residue is chromatographed on aluminum oxide (neutral, stage III) with a mixture of ethyl acetate/hexane. 2.32 g of the above-mentioned o-phenylene compound is obtained as white foam.
d) 18-Methyl-11beta,19-(4-methoxy-o-phenylene)-5alpha-hydroxy-3,3-(2,2-dimeth yltrimethylenedioxy)-androstan-17-one
Analogously to the directions described under example 2a), 2.2 g of the 17beta-hydroxy compound prepared under c) is reacted with chromium trioxide. 2.05 g of the above-mentioned compound is obtained as yellowish foam.
e) 18-Methyl-17-ethinyl-11beta,19-(4-methoxy-o-phenylene)-3,3-(2,2-dimethytri methylenedioxy)-androstane-5alpha,17beta-diol
190 ml of absolute tetrahydrofuran is saturated with ethine at 0.degree. C. Then 30.2 ml of a 1.6-m n-butyllithium solution (hexane) without any considerable increase of temperature is slowly instilled in this solution. After stirring for 15 more minutes, a solution of 2 g of the ketone prepared under d), dissolved in 35 ml of absolute tetrahydrofuran, is instilled slowly with ice-bath cooling into this reaction mixture and stirred for 30 more minutes. Then the reaction mixture is poured onto water, the aqueous phase is extracted with ethyl acetate and the organic phase is washed with sodium chloride solution. After drying on sodium sulfate and concentration by evaporation of the organic phase in a vacuum, the residue is chromatographed on aluminum oxide (neutral, stage III). 1.67 g of above-mentioned compound is obtained as white foam.
f) 18-Methyl-17-ethinyl-17beta-hydroxy-11beta,19-(4-methoxy-o-phenylene)-4-an drosten-3-one
Analogously to the directions described under example 1c), 1.6 g of the ethinyl compound prepared under e) is reacted. 918 mg of the title compound is obtained as white foam.
[.alpha.].sub.D.sup.22 =48.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 47
18-Methyl-17-(prop-1-inyl)-17beta-hydroxy-11beta,19-(4-dimethylamino-o-phen ylene)-4-androsten-3-one
a) 19-(2-Chloro-5-dimethylaminophenyl)-18-methyl-3,3-(2,2-dimethyltrimethylen edioxy)-9(11)-androstene-5alpha,17beta-diol
Analogously to the directions described under example 1a), 3.8 g of the epoxide prepared under example 46a) is reacted with 16.32 g of 2-chloro-5-dimethylaminobenzyl chloride. 3.1 g of the above-mentioned compound is obtained as white foam.
b) 18-Methyl-11beta,19-(dimethylamino-o-phenylene)-3,3-(2,2-dimethyltrimethyl enedioxy)-androstane-5alpha,17beta-diol
115 ml of anhydrous ammonia is condensed, with exclusion of moisture, in a round-bottom flask at -78.degree. C. After addition of 220 mg of lithium and appearance of the characteristic blue color, a solution of 3 g of the aryl halide prepared under a) is slowly instilled in 230 ml of tetrahydrofuran. After addition is completed, it is stirred for 20 more minutes and then the excess lithium is eliminated by instillation of ethanol. Then most of the ammonia is removed by evaporation, the reaction mixture is poured onto water and the aqueous phase is extracted several times with ethyl acetate. The combined organic phases are washed with sodium chloride solution, dried on sodium sulfate and concentrated by evaporation. The residue is chromatographed on aluminum oxide (neutral, stage III) with a mixture of ethyl acetate/hexane. 1.6 g of the above-mentioned compound is isolated as white foam.
c) 18-Methyl-11beta,19-(4-dimethylamino-o-phenylene)-5alpha-hydroxy-3,3-(2,2- dimethyltrimethylenedioxy)-androstan-17-one
Analogously to the directions described under example 13c), 1.5 g of the 17beta-hydroxy compound prepared under b) is oxidized. 1.24 g of the above-mentioned compound is obtained.
[.alpha.].sub.D.sup.22 =15.degree. (CHCl.sub.3 ; c=0.5); mp=274.degree.-278.degree. C. (ethyl acetate/hexane)
d) 18-Methyl-17-(prop-1-inyl)-11beta,19-(4-dimethylamino-o-phenylene)-3,3-(2, 2-dimethyltrimethylenedioxy)-androstane-5alpha,17beta-diol
Analogously to the directions described under example 2b), 1.2 g of the keto compound prepared under c) is converted into the corresponding 17alpha-propinyl compound. 1.14 g of the above-mentioned compound is obtained as white foam.
e) 18-Methyl-17-(prop-1-inyl)-17beta-hydroxy-11beta,19-(4-dimethylamino-o-phe nylene)-4-androsten-3-one
Analogously to the directions described in example 1c), 1.1 g of the propinyl compound prepared under d) is reacted. 602 mg of the title compound is obtained as a yellowish foam.
[.alpha.].sub.D.sup.22 =49.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 48
Anti-17beta-hydroxy-17-(3-hydroxyprop-1(Z)-enyl)-11beta,19-(4-dimethylamino -o-phenylene)-4-androsten-3-oxime and
EXAMPLE 49
Syn-17beta-hydroxy-17-(3-hydroxyprop-1(Z)-enyl)-11beta,19-(4-dimethylamino- o-phenylene)-4-androsten-3-oxime
Under protective gas, 1.15 g of the ketone prepared under example 17a) is put into 9 ml of absolute methylene chloride and mixed in succession with 28 ml of pyridine and 260 mg of hydroxylaminohydrochloride. After 3-hour stirring at room temperature the reaction mixture is poured onto saturated sodium bicarbonate solution and the aqueous phase is extracted with methylene chloride. The combined organic phases were dried on sodium sulfate and concentrated by evaporation in a vacuum. The residue is chromatographed on silica gel with a mixture of ethyl acetate/hexane and 453 mg of the antioxime and, as by-product, 287 mg of the syn-oxime are obtained.
48: .sup.1 H-NMR (CDCl.sub.3) [ ] 7.26 (1H, d J=9 Hz, proton on C-6 of the aromatic substance); 6.64 (1H, dd J=9 and J=2.5 Hz, proton on C-5 of the aromatic substance); 6.42 (1H, d J=2.5 Hz, proton on C-3 of the aromatic substance); 5.9 (1H,s, H-4); 5.62-5.8 (2H,m,H-20 and H-21); 4.23-4.4 (2H,m, protons on C-22); 2.9 (6H,s,protons of dimethylamino group); 0.5 (3H,s,protons on C-18)
49: .sup.1 H-NMR (CDCl.sub.3) [ ]: 7.25 (1H, d J=9 Hz,proton on C-6 of the aromatic substance); 6.6-6.7 (2H,m,H-4 and proton on C-5 of the aromatic substance); 6.42. (1H, d J=2 Hz, proton on C-3 of aromatic substance); 5.6-5.8 (2H,m,H-20 and H-21); 4.2-4.41 (2H, m, protons on C-22); 2.9 (6H,s,protons of the dimethylamino group); 0.5 (3H,s,protons on C-18)
EXAMPLE 50
17beta-Hydroxy-17-(3-hydroxyprop-1(Z)-enyl)-11beta,19-(4-dimethylamino-o-ph enylene)-1,4-androstadien-3-one
a) 17beta-Trimethylsilyloxy-17-(3-trimethylsilyloxyprop-1(Z)-enyl)-11beta,19- (4-dimethylamino-o-phenylene)-3-trimethylsilyloxy-2,4-androstadiene
2 g of the compound prepared according to example 17, dissolved in 60 ml of absolute tetrahydrofuran, is instilled in a solution of 43 mmol of lithium diisopropylamide in 200 ml of absolute tetrahydrofuran under protective gas at 0.degree. C. Then chlorotrimethylsilane (10.6 ml) is instilled in the reaction mixture. After 30-minutes stirring, the reaction solution is poured onto ice-cold saturated sodium bicarbonate solution, the aqueous phase is extracted with ethyl acetate and the organic phase is successively washed with water and ammonium chloride solution. After drying on sodium sulfate, the organic phase is concentrated by evaporation in a vacuum. 3.38 g of silylenol ether is obtained as raw product.
b) 17beta-Trimethylsilyloxy-17-(3-trimethylsilyloxyprop-1(Z)-enyl)-11beta,19- (4-dimethylamino-o-phenylene)-1,4-androstadien-3-one
3.38 g of the silylenol ether prepared under a) is suspended as raw product in 40 ml of absolute acetonitrile and mixed with 1.4 g of palladium (II) acetate. After 1-hour more stirring at room temperature, the reaction mixture is suctioned off over Celite and the filtrate is concentrated by evaporation in a vacuum. 3.3 g of the above-mentioned dienone is obtained as raw product.
c) 17beta-Hydroxy-17-(3-hydroxyprop-1(Z)-enyl)-11beta,19-(4-dimethylamino-o-p henylene)-1,4-androstadien-3-one
3.3 g of the dienone prepared under b) is dissolved in 40 ml of absolute methanol and mixed with 3 g of anhydrous potassium carbonate. Under protective gas, the reaction mixture is stirred for 1 more hour at room temperature, then poured onto saturated sodium chloride solution and the aqueous phase is extracted several times with methylene chloride. The combined organic phases are washed with saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. Chromatography of the residue on silica gel with a mixture of ethyl acetate/hexane results in 752 mg of the title compound as yellowish foam.
[.alpha.].sub.D.sup.22 =-95.degree. (CHCl.sub.3 ; c=0.44)
EXAMPLE 51
17beta-Hydroxy-17-ethinyl-11beta,19-(4-methoxy-o-phenylene)-4-androsten-3-o ne
a) 17-Ethinyl-11beta,19-(4-methoxy-o-phenylene)-3,3-(2,2-dimethyltrimethylene dioxy)-androstane-5alpha,17beta-diol
Analogously to the directions described under example 46e), 10 g of the keto compound prepared under example 4c) is converted into the corresponding 17alpha-ethinyl compound. 9.7 g of the above-mentioned compound is obtained as white foam.
b) 17beta-Hydroxy-17-ethinyl-11beta,19(4-methoxy-o-phenylene)-4-androsten-3-o ne
Analogously to the directions described under example 1c), 9.5 g of the ethinyl compound prepared under a) is reacted. 6.3 g of the title compound is obtained.
[.alpha.].sub.D.sup.22 =39.degree. (CDCl.sub.3 ; c=0.5); mp=248.degree.-151.degree. C. (ethyl acetate)
EXAMPLE 52
17beta-Hydroxy-17-ethinyl-11beta,19-(4-methoxy-o-phenylene)-1,4-androstadie n-3-one
a) 17beta-Trimethylsilyloxy-17-(2-trimethylsilylethinyl)-11beta,19-(4-methoxy -o-phenylene)-3-trimethylsilyloxy-2,4-androstadiene
Analogously to the directions described under example 50a), 1 g of the keto compound prepared under example 51 is converted into the corresponding silylenol ether. 1.54 g of the above-mentioned compound is obtained as raw product.
b) 17beta-Trimethysilyloxy-17-(2-trimethylsilylethinyl)-11beta,19-(4-methoxy- o-phenylene)-1,4-androstadien-3-one
Analogously to the directions described under example 50b), 1.54 g of the silylenol ether prepared under a) is converted into the corresponding dienone. 1.32 g of the above-mentioned compound is obtained as raw product.
c) 17beta-Hydroxy-17-ethinyl-11beta,19-(4-methoxy-o-phenylene)-1,4-androsten- 3-one
Analogously to the directions described under example 50c), 1.34 g of the dienone prepared under b) is converted into the title compound. 720 mg of the above-mentioned compound is isolated as white foam.
[.alpha.].sub.D.sup.22 =-131.degree. (CHCl.sub.3 ; c=0.5); mp=decomposition at 300.degree.-304.degree. C. (ethyl acetate)
EXAMPLE 53
17beta-Hydroxy-17-(2-bromoethinyl-11beta,19-(4-methoxy-o-phenylene)-4-andro sten-3-one
0.5 g of the acetylene prepared under example 51 is stirred for 30 minutes together 250 mg of N-bromosuccinimide and 21 mg of silver nitrate in 9 ml of acetone. Then the reaction mixture is filtered over Celite, the filter cake is thoroughly rewashed with methylene chloride, the filtrate is mixed with water and the aqueous phase is extracted several times with methylene chloride. The combined organic phases are washed with saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. The raw product is taken up in ethyl acetate and purified by crystallization. 421 mg of the title compound is obtained.
[.alpha.].sub.D.sup.22 =-11.degree. (CHCl.sub.3 ; c=0.5); mp=223.degree.-225.degree. C. (ethyl acetate)
EXAMPLE 54
11beta,19-(4-Dimethylamino-o-phenylene)-4-androsten-[17(beta-1')-spiro-5']- 2',5'-dihydrofuran-3-one
At 0.degree. C., 1 g of the steroid obtained under example 17 is put into 30 ml of absolute methylene chloride and mixed with 3 ml of triethylamine. After addition of 0.42 ml of methane sulfonic acid chloride the reaction mixture is stirred at 0.degree. C. for one more hour. Then it is poured on saturated sodium bicarbonate solution and the aqueous phase is extracted with methylene chloride. The combined organic phases are dried on sodium sulfate and concentrated by evaporation in a vacuum. The residue is chromatographed on silica gel with a mixture of ethyl acetate/hexane and 752 mg of the title compound is obtained as white foam.
[.alpha.].sub.D.sup.22 =83.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 55
17beta-Hydroxy-17-(3-hydroxypropyl)-11beta,19-(4-dimethylamino-o-phenylene) -4-androsten-3-one
a) 17-[3-(Tetrahydropyran-2-yloxy)-propyl]-11beta,19-(4-dimethylamino-o-pheny lene)-3,3-(2,2-dimethyltrimethylenedioxy)-androstan-5alpha,17beta-diol
5 g of the steroid prepared under example 16a) is put into 100 ml of ethanol and mixed with 0.5 g palladium/carbon (10%). Then it is stirred under normal pressure of a hydrogen atmosphere until one equivalent of hydrogen is taken up. Then the reaction solution is filtered over Celite, the filter cake is thoroughly rewashed with methylene chloride and the filtrate is concentrated by evaporation in a vacuum. The residue is chromatographed on aluminum oxide (neutral, stage III) with a mixture of ethyl acetate/hexane and thus 4.55 g of the above-mentioned compound is obtained as white foam.
b) 17beta-Hydroxy-17-(3-hydroxypropyl)-11beta,19-(4-dimethylamino-o-phenylene )-4-androsten-3-one
Analogously to the directions described under example 1c), 4.5 g of the hydroxypropyl compound prepared under a) is reacted. 2.49 g of the title compound is obtained.
[.alpha.].sub.D.sup.22 =81.degree. (CHCl.sub.3 ; c=0.5); mp=132.degree.-135.degree. C. (ethyl acetate)
EXAMPLE 56
11beta,19-(4-Dimethylamino-o-phenylene)-4-androsten-[17(beta-1')-spiro-5']- tetrahydrofuran-3-one
Under 0.degree. C., 1 g of the steroid obtained under example 55 is put into 30 ml of absolute methylene chloride and mixed with 3 ml of triethylamine. After addition of 0.42 ml of methane sulfonic acid chloride the reaction mixture is stirred for 2 more hours at room temperature. Then it is poured onto saturated sodium bicarbonate solution and the aqueous phase is extracted with methylene chloride. The combined organic phases are dried on sodium sulfate and concentrated by evaporation in a vacuum. The residue is chromatographed on silica gel with a mixture of ethyl acetate/hexane and 691 mg of the title compound is obtained. [.alpha.].sub.D.sup.22 =80.degree. (CHCl.sub.3 ; c=0.515); melting point=172.degree.-175.degree. C. (diisopropyl ether)
EXAMPLE 57
17beta-Hydroxy-17-ethinyl-11beta,19-(4-ethyl-o-phenylene)-4-androsten-3-one
a) 11beta,19-(4-Ethyl-o-phenylene)-4-androsten-3,17-one
Analogously to the directions described under example 1c), 15 g of the keto compound prepared under example 24a) is reacted. 8.3 g of the above-mentioned compound is obtained as white foam.
b) 11beta,19-(4-Ethyl-o-phenylene)-3-ethoxy-3,5-androstadien-17-one
8.2 g of the dione prepared under a) is dissolved in 500 ml of methylene chloride and, under protective gas, is mixed with 1.32 ml of absolute ethanol, 10 ml of triethylorthoformate and 160 mg of p-toluenesulfonic acid (dihydrate). After 4-hour stirring with ice-bath cooling the mixture is mixed with a little pyridine and then poured onto saturated sodium bicarbonate solution. The aqueous phase is separated and extracted with methylene chloride. The organic phases are washed with saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. 8.3 g of the raw product, whose purity is sufficient for further reaction, is obtained.
c) 17-Ethinyl-11beta,19-(4-ethyl-o-phenylene)-3-ethoxy-3,5-androstadien-17bet a-ol
Analogously to the directions described under example 46e), 10 g of the keto compound prepared under b) is converted into the corresponding 17alpha-ethinyl compound. 8.3 g of the above-mentioned compound is obtained as white foam.
d) 17beta-hydroxy-17-ethinyl-11beta,19-(4-ethyl-o-phenylene)-4-androsten-3-on e
Analogously to the directions described under example 1c), 2.8 g of the ethinyl compound prepared under c) is reacted. 1.98 g of the title compound is obtained.
[.alpha.].sub.D.sup.22 =45.degree. (CHCl.sub.3 ; c=0.5); melting point=242.degree.-248.degree. C. (ethyl acetate)
EXAMPLE 58
17beta-Hydroxy-17-ethinyl-11beta,19-(4-ethyl-o-phenylene)-4,6-androstadien- 3-one
Analogously to the directions described under example 3d), 5.3 g of the ethinyl compound prepared under example 57c) is reacted. 3.45 g of the title compound is obtained as yellowish foam.
[.alpha.].sub.D.sup.22 =161.degree. (CHCl.sub.3 ; c=0.52)
EXAMPLE 59
17beta-Hydroxy-17-ethinyl-11beta,19-(4-ethyl-o-phenylene)-6-chloro-4,6-andr ostadien-3-one
a) 17beta-Hydroxy-17-ethinyl-11beta,19-(4-ethyl-o-phenylene)-6alpha,7alpha-ep oxy-4-androsten-3-one
1.86 g of m-chloroperbenzoic acid (68%) is added to a solution of 2 g of the dienone prepared under example 58 in 100 ml of absolute methylene chloride at 0.degree. C. Then the reaction mixture is heated to room temperature and stirred for 24 more hours. It is diluted with methylene chloride, the organic phase is successively washed with saturated sodium thiosulfate solution, 5% sodium hydroxide solution and water, dried on sodium sulfate and concentrated by evaporation in a vacuum. The residue is chromatographed on silica gel with a mixture of ethyl acetate/hexane. 802 mg of the above-mentioned epoxide is obtained as a white foam.
b) 7alpha,17beta-Dihydroxy-17-ethinyl-11beta,19-(4-ethyl-o-phenylene)-6beta-c hloro-4,6-androstadien-3-one
750 mg of the epoxide prepared under a) is put into 15 ml of glacial acetic acid, mixed with 1.5 g of lithium chloride and stirred for 30 minutes at room temperature. Then the reaction mixture is poured onto water and the aqueous phase is extracted with methylene chloride. The combined organic phases are washed with saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. Final solvent residues are removed azeotropically with toluene. 947 mg of the above-mentioned compound is obtained as raw product.
c) 17beta-Hydroxy-17-ethinyl-11beta,19-(4-ethyl-o-phenylene)-6-chloro-4,6-and rostadien-3-one
1.14 g of 4-dimethylaminopyridine and 0.71 ml of trifluoromethane sulfonic acid anhydride, dissolved in 4.5 ml of absolute methylene chloride, are added to a solution of 900 mg of the chlorohydrin prepared under b) in 25 ml of absolute methylene chloride at -78.degree. C. Then the reaction mixture is heated to 0.degree. C. and stirred for 2 more hours at this temperature. Then it is poured onto saturated sodium bicarbonate solution and the aqueous phase is extracted several times with methylene chloride. The combined organic phases are washed with saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. The residue is chromatographed on silica gel with a mixture of ethyl acetate/hexane and 459 g of the title compound is obtained as yellowish foam.
[.alpha.].sub.D.sup.22 =163.degree. (CHCl.sub.3 ; c=0.515)
EXAMPLE 60
17beta-Hydroxy-17-vinyl-11beta,19-(4-ethyl-o-phenylene)-4,6-androstadien-3- one
Analogously to the directions described under example 5b), 700 mg of the ethinyl compound prepared under example 58 is reacted. 497 mg of the title compound is obtained after chromatography on silica gel with a mixture of ethyl acetate/hexane.
[.alpha.].sub.D.sup.22 =247.degree. (CHCl.sub.3 ; c=0.51); melting point=194.degree.-196.degree. C. (ethyl acetate)
EXAMPLE 61
17beta-Hydroxy-11beta,19-(4-iodo-o-phenylene)-4-androsten-3-one a) 11beta,19-(4-iodo-o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-androst ane-5alpha,17beta-diol
300 mg of the tin compound prepared under example 39alpha) is dissolved in 15 ml of absolute methylene chloride and mixed with 456 mg of iodine. After one more hour stirring, the reaction mixture is poured onto saturated sodium thiosulfate solution and the aqueous phase is extracted with methylene chloride. The combined organic phases are dried on sodium sulfate and concentrated by evaporation in a vacuum. The residue is chromatographed on aluminum oxide (neutral, stage III) with a mixture of ethyl acetate/hexane and 196 mg of the above-mentioned compound is obtained as yellowish foam.
b) 17beta-Hydroxy-11beta,19-(4-iodo-o-phenylene)-4-androsten-3-one
Analogously to the directions described under example 1c) 180 mg of the iodine compound prepared under a) is reacted. 118 mg of the title compound is obtained as yellowish foam.
.sup.1 H-NMR (CDCl.sub.3) [.delta.]: 7.48 (1H,dd,J=1.5 and J=8 Hz, proton on C-5 of the aromatic substance); 7.42, (1H, s,proton on C-3 of the aromatic substance); 7.19 (1H, d J=8 Hz, proton on C-6 of the aromatic substance); 5.87 (1H,s,H-4); 3.62-3.74 (1H,q, J=7.5 and J=15 Hz,H-17); 0.27 (3H,s,protons on C-18)
EXAMPLE 62
17-(prop-1-inyl)-17beta-hydroxy-11beta,19-(4-cyano-o-phenylene)-4-androsten -3-one
a) 11beta,19-(4-cyano-o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-andros tane-5alpha,17beta-diol
800 mg of the triflate obtained under example 26b) is dissolved in 2.5 ml of absolute tetrahydrofuran and under protective gas is mixed with 15 mg of palladium tetrakistriphenylphosphine and 98 mg of potassium cyanide. The reaction mixture is refluxed for 40 hours, then cooled to room temperature and filtered over Celite. The filter cake is thoroughly rewashed with methylene chloride, the filtrate is concentrated by evaporation in a vacuum and the residue is chromatographed on aluminum oxide (neutral, stage III) with a mixture of ethyl acetate/hexane. 455 mg of above-mentioned compound is isolated as yellowish foam.
b) 17-(Prop-1-inyl)-11beta,19-(4-cyano-o-phenylene)-3,3-(2,2-dimethyltrimethy lenedioxy)-androstan-5alpha,17beta-diol
Analogously to the directions described under example 2b), 425 mg of the keto compound prepared under a) is converted into the corresponding 17alpha-propinyl compound. 355 mg of the above-mentioned compound is obtained as white foam.
c) 17beta-Hydroxy-17-(prop-1-inyl)-11beta,19-(4-cyano-o-phenylene)-4-androste n-3-one
Analogously to the directions described under example 1c) 350 mg of the propinyl compound prepared under b) is reacted. 224 mg of the title compound is obtained.
[.alpha.].sub.D.sup.22 =33.degree. (CHCl.sub.3 ; c=0.5); melting point=232.degree.-235.degree. C. (ethyl acetate/diisopropylether)
EXAMPLE 63
17beta-Hydroxy-17-ethinyl-11beta,19-(4-ethyl-o-phenylene)-7alpha-methyl-4-a ndrosten-3-one
150 mg of copper(I) chloride is added to 30 ml of a 1-m solution of methylmagnesium iodide solution in diethyl ether in an ice-cold bath. After stirring for 15 more minutes, a solution of 1.24 g of the dienone prepared under example 58 is instilled in 15 ml of absolute tetrahydrofuran. The reaction mixture is stirred for 2 more hours and then poured onto saturated ammonium chloride solution. The aqueous phase is extracted with ethyl acetate, the organic phase is washed with dilute ammonia solution and saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. The residue is chromatographed on silica gel with a mixture of ethyl acetate/hexane. 453 mg of the title compound is isolated.
[.alpha.].sub.D.sup.22 =33.degree. (CHCl.sub.3 ; c=0.5); melting point=260.degree.-264.degree. C. (ethyl acetate)
EXAMPLE 64
17beta-Hydroxy-17-ethinyl-11beta,19-(4-methoxy-o-phenylene)-6-methylene-4-a ndrosten-3-one
834 mg of the enone obtained according to example 51 is dissolved in 22 ml of absolute chloroform and successively mixed with 738 mg of anhydrous sodium acetate, 14.4 ml of formaldehyde diethyl acetal and 2.8 ml of phosphoryl chloride. The reaction mixture is then refluxed for 1 hour, neutralized with sodium carbonate solution and the aqueous phase is extracted with methylene chloride, the combined organic phases are washed with water, dried on sodium sulfate and concentrated by evaporation in a vacuum. The residue is chromatographed on silica gel with a mixture of ethyl acetate/hexane and 347 mg of the title compound is obtained as yellowish foam.
.sup.1 H-NMR (CD.sub.2 Cl.sub.2) [.delta.]: 7.32 (1H,dJ=9 Hz, proton on C-6 of the aromatic substance); 6.75 (1H,dd J=9 and J=2,5 Hz, proton on C-5 of the aromatic substance); 6.59 (1H,d J=2.5 Hz, proton on C-3 of the aromatic substance); 6.01 (1H,s,H-4); 5.2 and 5.03 (respectively: 1H,tr J=1.5 Hz, proton of the exomethylene group); 3.75 (3H,s, protons of the methyl ether group; 0.39 (3H,s, protons on C-18)
EXAMPLE 65
11beta,19-(4-Dimethylamino-o-phenylene)-4-pregnene-3,20-dione
a) 17beta-Cyano-11B,19-(4-dimethylamino-o-phenylene)-3,3-(2,2-dimethyltrimeth ylenedioxy)-androstan-5alpha-ol
1.9 g of the steroid prepared according to example 13c) is dissolved under protective gas in 250 ml of absolute dimethoxyethane and mixed at room temperature with 12.5 g of potassium-t-butylate and 1.85 ml of t-butanol. 2.16 g of p-tolylsulfonylmethylisocyanide, dissolved in 50 ml of absolute dimethoxyethane, is slowly instilled in this mixture over 2 hours. After stirring for 30 more minutes, the reaction mixture is poured onto cold saturated ammonium chloride and the aqueous phase is extracted with methylene chloride. The combined organic phases are washed with saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. After chromatography on aluminum oxide (neutral, stage III) with a mixture of ethyl acetate/hexane, 1.67 g of the above-mentioned nitrile is obtained as yellowish foam.
b) 11beta,19-(4-Dimethylamino-o-phenylene)-4-pregnene-3,20-dione
1.5 g of the nitrile obtained under a) is put into 36 ml of absolute tetrahydrofuran under protective gas at 0.degree. C. and mixed with 18 ml of a 1.6 m methyllithium solution (diethyl ether). After stirring for 1.5 more hours, the reaction mixture is poured onto cold saturated ammonium chloride solution and the aqueous phase is extracted with ethyl acetate. The combined organic phases are washed with water, dried on sodium sulfate and concentrated by evaporation in a vacuum. 1.24 g of raw product is obtained.
1.24 g of the obtained raw product is dissolved in 120 ml of acetone and mixed, under protective gas, with 7.5 ml of 4 n of aqueous hydrochloric acid. After 2-hour stirring at 40.degree. C., the reaction mixture is poured onto cold saturated sodium bicarbonate solution and the aqueous phase is extracted several times with methylene chloride. The combined organic phases are dried on sodium sulfate and concentrated by evaporation in a vacuum. The residue is chromatographed on silica gel with a mixture of ethyl acetate/hexane. 764 mg of the title compound is obtained as yellowish foam.
.sup.1 H-NMR (CD.sub.2 Cl.sub.2) [.delta.]: 7.24 (1H,d J=9 Hz, proton 9 on C-6 of the aromatic substance); 6.61 (1h,dd J=9 and J=2,5 Hz, proton on C-5 of the aromatic substance); 6.42 (1H,d J=2, 5 Hz, proton on C-3 of the aromatic substance); 5.8 (1H,s,H-4); 2.9 (6H,s, protons of dimethylamino group); 2.18 (3H,s, protons on C-21); 0.18 (3H,s, protons on C-18)
EXAMPLE 66
17-(Prop-1-inyl)-17beta-hydroxy-11beta,19-(4-dimethylamino-o-phenylene)-4,6 -androstadien-17beta-ol
a) 17-(Prop-1-inyl)-11beta,19-(4-dimethylamino-o-phenylene)-3-ethoxy-3,5-andr ostadien-17beta-ol
Starting from 8 g of the keto compound obtained according to example 13c), by acid cleavage, according to directions 1c), of 5.4 g of 11beta,19-(4-dimethylamino-o-phenylene)-4-androstene-3,17-dione, by enol ether formation, according to directions 57b), of 3.14 g of 11beta,19-(4-dimethylamino-o-phenylene)-3-ethoxy-3,5-andostadien-17-one and propine addition, according to the directions of example 2b), 3.56 g of the above-mentioned compound is obtained as raw product.
b) 17-(Prop-1-inyl)-17beta-Hydroxy-11beta,19-(4-dimethylamino-o-phenylene-6be ta-bromo-4-androsten-3-one
3.5 g of the steroid obtained under a) is dissolved in 350 ml of methylene chloride and mixed with 1.2 ml triethylamine. Then the solution is cooled to -50.degree. C. and mixed at this temperature with 1.44 g of N-bromosuccinimide. After stirring for 15 more minutes at -50.degree. C., the reaction mixture is heated to 0.degree. C. and mixed with saturated sodium thiosulfate solution. Then the aqueous phase is separated and extracted with methylene chloride. The combined organic phases are washed with saturated ammonium chloride solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. After chromatography on silica gel with a mixture of ethyl acetate/hexane, 1.62 g of the title compound is obtained as white foam.
c) 17-(Prop-1-inyl)-17beta-Hydroxy-11beta,19-(4-dimethylamino-o-phenylene)-4, 6-androstadien-3-one
1.6 g of the 6beta-bromine compound prepared under b) analogously to the conditions described under example 3d) is converted with lithium carbonate into the dienone. 1.19 g of the title compound is obtained.
[.alpha.].sub.D.sup.22 =177.degree. (CHCl.sub.3 ; c=0.5); melting point=244.degree.-246.degree. C. (ethyl acetate)
EXAMPLE 67
17beta-Hydroxy-17-ethinyl-11beta,19-(4-ethyl-o-phenylene)-1,4-androstadien- 3-one
Analogously to example 50, 2 g of the enone obtained according to example 57 is converted into 741 mg of the title compound by way of 17beta-trimethylsilyloxy-17-(2-trimethylsilylethinyl)-11beta,19-(4-ethyl-o -phenylene)-3-trimethylsilyloxy-2,4-androstadiene and 17beta-trimethylsilyloxy-17-(2-trimethylsilylethinyl)-11beta,19-(4-ethyl-o -phenylene)-1,4-androstadien-3-one as intermediate steps.
[.alpha.].sub.D.sup.22 =-144.degree. C. (CHCl.sub.3 ; c=0.5); melting point=262.degree.-270.degree. C. (ethyl acetate)
EXAMPLE 68
17beta-Hydroxy-17-(prop-1-inyl)-11beta,19-(4-ethyl-o-phenylene)-1,4-androst adien-3-one
Analogously to example 50, 1 g of the enone obtained according to example 24 is converted into 306 mg of the title compound by way of 17beta-trimethylsilyloxy-17-(prop-1-inyl)-11beta,19-(4-ethyl-o-phenylene)- 3-trimethylsilyloxy-2,4-androstadiene and 17beta-trimethylsilyloxy-17-(prop-1-inyl)-11beta,19-(4-ethyl-o-phenylene)- 1,4-androstadine-3-one as intermediate steps.
[.alpha.].sub.D.sup.22 =-142.degree. CHCl.sub.3 ; c=0.52); mp=decomposition at 275.degree.-280.degree. C. (ethyl acetate)
EXAMPLE 69
17beta-Hydroxy-17-(prop-1-inyl)-11beta,19-[4-(4-cyanophenyl)-o-phenylene]-4 -androsten-3-one
Analogously to example 43, starting from 1.5 g of the trifluorate prepared according to example 26b), 373 mg of the title compound is obtained as white foam by way of 11beta,19-[4(4-cyanophenyl)-o-phenylene]-5alpha-hydroxy-3,3-(2,2-dimethylt rimethylenedioxy)-androstan-17-one and 17-(prop-1-inyl)-11beta,19-[4-(4-cyanophenyl)-o-phenylene]-3,3-(2,2-dimeth yltrimethylenedioxy)-androstane-5alpha,17beta-diol as intermediate steps.
[.alpha.].sub.D.sup.22 =76.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 70
17beta-Hydroxy-17-(prop-1-inyl)-11beta,19-[4-(2-thiazolyl)-o-phenylene]-4-a ndrosten-3-one
Analogously to example 43, starting from 1.5 g of the trifluorate prepared according to example 26b), 173 mg of the title compound is obtained as white foam by way of 11beta,19-[4-(2-thiazolyl)-o-phenylene]-5alpha-hydroxy-3,3-(2,2-dimethyltr imethylenedioxy)-androstan-17-one and 17-(prop-1-inyl)-11beta,19-[4-(2-thiazolyl)-o-phenylene]-3,3-(2,2-dimethyl trimethylenedioxy)-androstan-5alpha,17beta-diol as intermediate steps.
[.alpha.].sub.D.sup.22 =41.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 71
17beta-Hydroxy-17-(prop-1-inyl)-11beta,19-[4-(3-pyridyl)-o-phenylene]-4-and rosten-3-one
Analogously to example 43, starting from 1.5 g of the trifluorate prepared according to example 26b), 254 mg of the title compound is obtained as white foam by way of 11beta,19-[4-(3-pyridyl)-o-phenylene]-5alpha-hydroxy-3,3-(2,2-dimethyltrim ethylenedioxy)-androstan-17-one and 17-(prop-1-inyl)-11beta,19-[4-(3-pyridyl)-o-phenylene]-3,3-(2,2-dimethyltr imethylenedioxy)-androstane-5alpha,17beta-diol as intermediate steps.
[.alpha.].sub.D.sup.22 =51.degree. (CHCl.sub.3 ; c=0.505)
EXAMPLE 72
17beta-Hydroxy-17-(prop-1-inyl)-11beta,19-(3-ethinyl-o-phenylene)-4-androst en-3-one
a) 11beta,19-(3-hydroxy-o-phenylene)-3,3-(2,2-dimethyltrimethylenedioxy)-andr ostane-5alpha,17beta-diol
4 g of the methylenedioxy compound obtained according to example 45b) is dissolved in 300 ml of tetrahydrofuran and is added, at -78.degree. C., to 600 mg of lithium, dissolved in 160 ml of liquid ammonia, the reaction mixture is slowly heated to -40.degree. C. over three hours, then the excess lithium is decomposed by addition of ethanol and the ammonia is evaporated. The remaining phase is mixed with water and the aqueous phase is extracted with ethyl acetate. The combined organic phases are dried on sodium sulfate and concentrated by evaporation in a vacuum. After chromatography of the residue on silica gel with a mixture of ethyl acetate/hexane, 2.38 g of the above-mentioned compound is obtained. In addition, 0.45 g of the 4-hydroxy compound already prepared under example 18a) is isolated as by-product.
b) 11beta,19-(3-trifluoromethylsulfonyloxy-o-phenylene)-3,3-(2,2-dimethyltrim ethylenedioxy)-androstane-5alpha,17beta-diol
Analogously to the directions described under example 19a) 2.3 g of the 3-phenol obtained under a) is reacted with trifluoromethanesulfonic acid anhydride to obtain 1.67 g of the above-mentioned compound.
c) 17beta-Hydroxy-17-(prop-1-inyl)-11beta,19-(3-ethinyl-o-phenylene)-4-andros ten-3-one
207 mg of the title compound is prepared by coupling of 1.6 g of the trifluorate with ethinyltrimethylsilane analogously to the directions of example 20a) to 11beta,19-[3-(2-trimethylsilylethinyl)-o-phenylene]-3,3-(2,2-dimethyltrime thylenedioxy)-androstane-5alpha,17beta-diol, chromotrioxidation analogously to the directions of example 21c) to 11beta,19-[3-(2-trimethylsilyethinyl)-o-phenylene]-5alpha-hydroxy-3,3-(2,2 -dimethyltrimethylenedioxy)-androstan-17beta-one, desilylation analogously to the directions of 22a) to 11beta,19-(3-ethinyl-o-phenylene)-5alpha-hydroxy-3,3-(2,2-dimethyltrimethy lenedioxy)-androstan-17beta-one, propine addition analogously to the directions of example 22b) to 17-(prop-1-inyl)-11beta,19-(3-ethinyl-o-phenylene)-3,3-(2,2-dimethyltrimet hylenedioxy)-androstane-5alpha,17beta-diol and its cleavage analogously to the directions of 1c).
[.alpha.].sub.D.sup.22 =-32.degree. (CHCl.sub.3 ; c=0.5)
EXAMPLE 73
17-(Prop-1(2)-enyl)-17beta-hydroxy-11beta,19-(3-bromo-4-dimethylamino-o-phe nylene)-4-androsten-3-one
1.5 g of the steroid obtained under example 17 is dissolved in 150 ml of methylene chloride and mixed with 4.7 ml of triethylamine. Then the solution is cooled to 0.degree. C. and at this temperature is mixed with 578 mg of N-bromosuccinimide. After stirring for 3 more hours at 0.degree. C., the reaction mixture is mixed with saturated sodium thiosulfate solution. Then the aqueous phase is separated and extracted with methylene chloride. The combined organic phases are washed with saturated sodium chloride solution, dried on sodium sulfate and concentrated by evaporation in a vacuum. After chromatography on silica gel with a mixture of ethyl acetate/hexane, 1.03 g of the title compound is obtained as yellowish foam.
.sup.1 H-NMR (CD.sub.2 Cl.sub.2) [.delta.]: 7.39 (1H, d J=9 Hz, proton on C-6 of the aromatic substance); 7.0 (1H, d J=9, proton on C-5 of the aromatic substance); 5.85 (1H,s,H-4); 5.6-5.8 (2H,m,protons on C-20 and C-21); 2.75 (6H,s,protons of the dimethylamino group); 0.38 (3H,s,protons on C-18).
Claims
We claim:
1. A 19, 11.beta.-bridged steroid of general formula I ##STR20## wherein R.sup.1 is a methyl or ethyl radical; R.sup.2 is hydrogen, chlorine or C.sub.1 -C.sub.4 -alkyl radical; B and G, being the same or different, are each hydroge or C.sub.1 -C.sub.4 -alkyl radical; B and G, together, can also be a second bond between carbon atoms 6 and 7; B and R.sup.2, together, can also be a methylene or ethylene group; Z is a substituted or unsubstituted, saturated or unsaturated, 5- or 6-member ring; V is an unsubstituted or substituted, carbocyclic or heterocyclic, aryl radical; ring A is ##STR21## wherein M and N, together, are a second bond, or M is hydrogen and N is hydroxy, in which case B, R.sup.2, G, R.sup.3, D and E are all each hydrogen. X is an oxygen atom, two hydrogen atoms or one hydroxyimino group (N.about.OH), R.sup.3 and D, being the same or different, are each hydrogen nitrile, or C.sub.1 -C.sub.4 -alkyl radical, R.sup.3 and D, together, can also be a methylene or ethylene group, E is hydrogen or C.sub.1 -C.sub.4 -alkyl radical, D and E, together, can also be a second bond between carbon atoms 1 and 2 or, together, can also be a methylene group; or Ring A is ##STR22## or Ring A is ##STR23## wherein R.sup.11 is hydrogen or C.sub.1 -C.sub.8 -alkyl radical; and pharmaceutically tolerated acid addition salts thereof.
2. A compound in accordance with claim 1, wherein R.sup.2, B and G are each a hydrogen atom.
3. A compound in accordance with claim 1, wherein B and G, together, are a second bond and R.sup.2 is a hydrogen atom.
4. A compound in accordance with claim 1, wherein V is a phenyl ring according to the formula ##STR24## wherein R.sup.4 and R.sup.4', being the same or different, are each hydrogen, cyanide, --OR.sup.11 --, --S(O).sub.k R.sup.11 --, N(O).sub.n R.sup.11 R.sup.12 --, --O--SO.sub.2 R.sup.13 --, --P(O) (OR.sup.14).sub.2 --, SiR.sub.3.sup.14 -- or SnR.sub.3.sup.14 --; R.sup.11 is hydrogen or C.sub.1 -C.sub.8 -alkyl radical; R.sup.12 is R.sup.11, cyanide or C.sub.1 -C.sub.10 -acyl radical; R.sup.13 is perfluorated C.sub.1 -C.sub.4 -alkyl radical; R.sup.14 is C.sub.1 -C.sub.4 -alkyl radical; R.sup.11 and R.sup.12, in an --N(O).sub.n R.sup.11 R.sup.12 group, can also be, together with the inclusion of N, a 5- or 6-member heterocyclic ring, optionally containing another heteroatom selected from N, O or S; Y and Y', being the same or different, are each a direct bond, a straight-chain or branched alkylene group having up to 20 carbon atoms, optionally containing double or triple bond(s), and optionally substituted with one or more oxo--, C.sub.1 -C.sub.10 -acyloxy-, --OR.sup.11 --, --S(O).sub.k R.sup.11 -- and/or --N(O).sub.n R.sup.11 R.sup.12 -- groups, or a substituted or unsubstituted aryl radical; R.sup.4 --Y and R.sup.4' --Y', together, can also be substituted or unsubstituted, saturated or unsaturated or aromatic, 5-or 6-member ring with 0 to 2 oxygen, sulfur atoms and/or --NR.sup.11 -- groups; k is 0, 1 or 2; and n is 0 or 1; with the proviso that k and n are greater than 0 only if R.sup.11 is a C.sub.1 -C.sub.8 -alkyl radical.
5. A compound in accordance with claim 4, wherein Y and Y' are each a direct bond and R.sup.4 and R.sup.4' are each a hydrogen atom.
6. A compound in accordance with claim 4, wherein Y and Y' are each a direct bond, R.sup.4 is a hydrogen atom, R.sup.4' is N(O).sub.n R.sup.11 R.sup.12, n is 0, and R.sup.11 and R.sup.12 are each C.sub.1 -C.sub.8 -alkyl.
7. A compound in accordance with claim 4, wherein Y and Y' are each a direct bond, R.sup.4 is a hydrogen atom, and R.sup.4' is a C.sub.1 -C.sub.8 alkoxy group.
8. A compound in accordance with claim 4, wherein Y is a direct bond, R.sup.4 and R.sup.4' are each a hydrogen atom, and Y' is a straight-chain or branched alkylene group having up to 20 carbon atoms, optionally containing double and/or triple bond(s), and which is substituted with an oxo- or OR.sup.11 -group, R.sup.11 being a hydrogen atom or a C.sub.1 -C.sub.8 -alkyl radical.
9. A compound in accordance with claim 4, wherein R.sup.4 --Y and R.sup.4' --Y together are a saturated, unsaturated or aromatic 5- or 6-member ring with 0 to 2 oxygen, sulfur atoms and/or --NR.sup.11 -groups with R.sup.11 being a hydrogen atom or a C.sub.1 -C.sub.8 -alkyl radical.
10. A compound in accordance with claim 4, wherein Y'--R.sup.4' is a hydrogen atom, and Y--R.sup.4 is ethyl, vinyl, isopropyl, isopropenyl, prop-1(Z)-enyl, prop-1(E)-enyl, prop-2-enyl, ethinyl, propinyl, prop-2-inyl, methoxy, thiomethyl, thioethyl, 1-hydroxyethyl, diethoxyphosphoryl, trifluoromethyl sulfonate, or a substituted or unsubstituted, carbocyclic or heterocyclic aryl radical.
11. A compound in accordance with claim 10, wherein Y--R.sup.4 is phenyl, naphthyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-tolyl, 3-tolyl, 4-tolyl, 2-dimethylamino, 3-dimethylamino, 4-dimethylamino, furyl-2, furyl-3, thienyl-2, thienyl-3, pyridyl-2, pyridyl-3, pyridyl-4, thiazolyl, or imidazolyl.
12. A compound in accordance with claim 4, wherein V is furyl, thienyl, pyridyl, pyrazolyl, pyrrolyl, pyrimidinyl, oxazolyl, pyridazinyl, or pyrazinyl.
13. A compound in accordance with claim 1, wherein V is a 5- or 6-member heteroaromatic ring with 1 to 2N, O or S atoms of the formula ##STR25## wherein R.sup.4 and R.sup.4', being the same or different, are each hydrogen, cyanide, --OR.sup.11 --, --S(O).sub.k R.sup.11 --, N(O).sub.n R.sup.11 R.sup.12 --, --O--SO.sub.2 R.sup.13 --, --P(O) (OR.sup.14).sub.2 --, SiR.sub.3.sup.14 -- or SnR.sub.3.sup.14 --; R.sup.11 is hydrogen or C.sub.1 -C.sub.8 -alkyl radical; R.sup.12 is R.sup.11, cyanide or C.sub.1 -C.sub.10 -acyl radical; R.sup.13 is perfluorated C.sub.1 -C.sub.4 -alkyl radical; R.sup.14 is C.sub.1 -C.sub.4 -alkyl radical; R.sup.11 and R.sup.12, in an --N(O).sub.n R.sup.11 R.sup.12 group, can also be, together with the inclusion of N, a 5- or 6-member heterocyclic ring, optionally containing another heteroatom selected from N, O or S; Y and Y', being the same or different, are each a direct bond, a straight-chain or branched alkylene group having up to 20 carbon atoms, optionally containing double or triple bond(s), and optionally substituted with one or more oxo-, C.sub.1 -C.sub.10 -acyloxy-, --OR.sup.11 --, --S(O).sub.k R.sup.11 -- and/or --N(O).sub.n R.sup.11 R.sup.12 -- groups, or a substituted or unsubstituted aryl radical; R.sup.4 --Y and R.sup.4' --Y', together, can also be substituted or unsubstituted, saturated or unsaturated or aromatic, 5-or 6-member ring with 0 to 2 oxygen, sulfur atoms and/or --NR.sup.11 -- groups; k is 0, 1 or 2; and n is 0 or 1; with the proviso that k and n are greater than 0 only if R.sup.11 is a C.sub.1 -C.sub.8 -alkyl radical.
14. A compound in accordance with claim 1, wherein Z is a ring according to the formula ##STR26## wherein -- is a single bond or a double bond; W is CH.sub.2 --, CH--, CH.sub.2 CH.sub.2 -- or CHCH.sub.2 --; and R.sup.5 and R.sup.6 are, respectively, --OR.sup.7 and --C.tbd.C--U, ##STR27## wherein R.sup.7 is hydrogen or C.sub.1 -C.sub.4 -acyl radical, U is hydrogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -hydroxyalkyl, C.sub.1 -C.sub.4 -alkoxyalkyl, C.sub.1 -C.sub.4 -aclyoxyalkyl, or halogen, R.sup.8 is hydrogen, hydroxy, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -O-alkyl, or C.sub.1 -C.sub.4 -O-acyl, R.sup.9 is hydrogen, hydroxy, cyanide, a C.sub.1 -C.sub.4 -alkyl, or C.sub.1 -C.sub.4 -O-acyl, R.sup.10 is hydrogen, C.sub.1 -C.sub.10 -alkyl, or C.sub.1 -C.sub.10 -acyl, m is 0, 1, 2 or 3, and k is 0, 1 or 2.
15. A pharmaceutical composition comprising an effective amount of a compound of claim 1, and a pharmaceutically acceptable carrier.
16. A 19, 11.beta.-bridged steroid of general formula I ##STR28## wherein R.sup.1 is a methyl or ethyl radical; R.sup.2 is hydrogen, chlorine or C.sub.1 -C.sub.4 -alkyl radical; B and G, being the same or different, are each hydrogen or C.sub.1 -C.sub.4 -alkyl radical; B and G, together, can also be a second bond between carbon atoms 6 and 7; B and R.sup.2, together, can also be a methylene or ethylene group; Z is a ring according to the formula ##STR29## wherein -- is a single bond or a double bond; W is CH.sub.2 --, CH--, CH.sub.2 CH.sub.2 -- or CHCH.sub.2 --; and R.sup.5 and R.sup.6 are, respectively, --OR.sup.7 and --C.tbd.C--U, ##STR30## --OR.sup.7 and --(CH.sub.2).sub.m --CH.sub.2 --R.sup.9, --OR.sup.7 and --CH.dbd.CH--(CH.sub.2).sub.k --CH.sub.2 --R.sup.9, --OR.sup.10 and --H, or --OR.sup.10 and --(CH.sub.2).sub.k --C.tbd.C--U, or R.sup.5 and R.sup.6 together are ##STR31## R.sup.7 is hydrogen or C.sub.1 -C.sub.4 -acyl radical, U is hydrogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -hydroxyalkyl, C.sub.1 -C.sub.4 -alkoxyalkyl, C.sub.1 -C.sub.4 -aclyoxyalkyl, or halogen, R.sup.8 is hydrogen, hydroxy, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -O-alkyl, or C.sub.1 -C.sub.4 -O-acyl, R.sup.9 is hydrogen, hydroxy, cyanide, a C.sub.1 -C.sub.4 -alkyl, or C.sub.1 -C.sub.4 -O-acyl, R.sup.10 is hydrogen, C.sub.1 -C.sub.10 -alkyl, or C.sub.1 -C.sub.10 -acyl, m is 0, 1, 2 or 3, and k is 0, 1 or 2; V is a 5- or 6-member heteroaromatic ring with 1 to 2N, O or S atoms of the formula ##STR32## or V is a phenyl ring according to the formula ##STR33## wherein R.sup.4 and R.sup.4', being the same or different, are each hydrogen, cyanide, --OR.sup.11, --S(O).sub.k R.sup.11, N(O).sub.n R.sup.11 R.sup.12 --; --O--SO.sub.2 R.sup.13, --P(O) (OR.sup.14).sub.2, SiR.sup.14.sub.3 -- or SnR.sup.14.sub.3 --; R.sup.11 is hydrogen or C.sub.1 -C.sub.8 -alkyl radical; R.sup.12 is R.sup.11, cyanide or C.sub.1 -C.sub.10 -acyl radical; R.sup.13 is perfluorated C.sub.1 -C.sub.4 -alkyl radical; R.sup.14 is C.sub.1 -C.sub.4 -alkyl radical; R.sup.11 and R.sup.12, in an --N(O).sub.n R.sup.11 R.sup.12 group, can also be, together with the inclusion of N, a 5- or 6-member heterocyclic ring, optionally containing another heteroatom selected from N, O or S; Y and Y' being the same or different, are each a direct bond, a straight-chain or branched alkylene group having up to 20 carbon atoms, optionally containing double or triple bond(s), and optionally substituted with one or more oxo-, C.sub.1 -C.sub.10 -acyloxy-, --OR.sup.11, --S(O).sub.k R.sup.11 and/or --N(O).sub.n R.sup.11 R.sup.12 groups, or a substituted or unsubstituted aryl radical; R.sup.4-Y and R.sup.4'-Y', together, can be substituted or unsubstituted, saturated or unsaturated or aromatic, 5- or 6-member ring with 0 to 2 oxygen sulfur atoms and/or --NR.sup.11 -- groups; k is 0, 1 or 2; and n is 0 or 1; with the proviso that for group V, k and n are greater than 0 only if R.sup.11 is a C.sub.1 -C.sub.8 -alkyl radical; ring A is ##STR34## wherein M and N, together, are a second bond, or M is hydrogen and N is hydroxy, in which case B, R.sup.2, G, R.sup.3, D and E are all each hydrogen, X is an oxygen atom, two hydrogen atoms or one hydroxyimino group (N--OH), R.sup.3 and D, being the same or different, are each hydrogen nitrile, or C.sub.1 -C.sub.4 -alkyl radical, R.sup.3 and D, together, can also be a methylene or ethylene group, E is hydrogen or C.sub.1 -C.sub.4 -alkyl radical, D and E, together, can also be a second bond between carbon atoms 1 and 2 or, together, can also be a methylene group; or Ring A is ##STR35## or Ring A is ##STR36## wherein R.sup.11 is hydrogen or C.sub.1 -C.sub.8 -alkyl radical; and pharmaceutically tolerated acid additions salts thereof.
17. A 19, 11.beta.-bridged steroid of general formula I ##STR37## wherein R.sup.1 is a methyl or ethyl radical; R.sup.2 is hydrogen, chlorine or C.sub.1 -C.sub.4 -alkyl radical; B and G, being the same or different, are each hydrogen or C.sub.1 -C.sub.4 -alkyl radical; B and G, together, can also be a second bond between carbon atoms 6 and 7; B and R.sup.2, together, can also be a methylene or ethylene group; Z is a ring according to the formula ##STR38## wherein -- is a single bond or a double bond; W is CH.sub.2 --, CH--, CH.sub.2 CH.sub.2 -- or CHCH.sub.2 --; and R.sup.5 and R.sup.6 are, respectively, --OR.sup.7 and --C.tbd.C--U, ##STR39## --OR.sup.7 and --(CH.sub.2).sub.m --CH.sub.2 --R.sup.9, --OR.sup.7 and --CH.dbd.CH--(CH.sub.2).sub.k --CH.sub.2 --R.sup.9, --OR.sup.10 and --H, or --OR.sup.10 and --(CH.sub.2).sub.k --C.tbd.C--U, or R.sup.5 and R.sup.6 together are ##STR40## wherein R.sup.7 is hydrogen or C.sub.1 -C.sub.4 -acyl radical, U is hydrogen, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -hydroxyalkyl, C.sub.1 -C.sub.4 -alkoxyalkyl, C.sub.1 -C.sub.4 -acyloxyalkyl, or halogen, R.sup.8 is hydrogen, hydroxy, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -O-alkyl, or C.sub.1 -C.sub.4 -O-acyl, R.sup.9 is hydrogen, hydroxy, cyanide, a C.sub.1 -C.sub.4 -alkyl, or C.sub.1 -C.sub.4 -O-acyl R.sup.10 is hydrogen, C.sub.1 -C.sub.10 -alkyl, or C.sub.1 -C.sub.10 -acyl, m is 0, 1, 2 or 3, and k is 0, 1 or 2; V is a phenyl ring according to the formula ##STR41## wherein R.sup.4 and R.sup.4', being the same or different, are each hydrogen, cyanide, --OR.sup.11, --S(O).sub.k R.sup.11, N(O).sub.n R.sup.11 R.sup.12 --, --O--SO.sub.2 R.sup.13, --P(O) (OR.sup.14).sub.2, SiR.sup.14.sub.3 -- or SnR.sup.14.sub.3 --, R.sup.11 is hydrogen or C.sub.1 -C.sub.8 -alkyl radical, R.sup.12 is R.sup.11, cyanide or C.sub.1 -C.sub.10 -acyl radical, R.sup.13 is perfluorated C.sub.1 -C.sub.4 -alkyl radical, R.sup.14 is C.sub.1 -C.sub.4 -alkyl radical, R.sup.11 and R.sup.12, in an --N(O).sub.n R.sup.11 R.sup.12 group, can also be, together with the inclusion of N, a 5- or 6-member heterocyclic ring, optionally containing another heteroatom selected from N, O or S, Y and Y', being the same or different, are each a direct bond, a straight-chain or branched alkylene group having up to 20 carbon atoms, optionally containing double or triple bond(s), and optionally substituted with one or more oxo-, C.sub.1 -C.sub.10 -acyloxy-, --OR.sup.11, --S(O).sub.k R.sup.11 and/or --N(O).sub.n R.sup.11 R.sup.12 groups, or a substituted or unsubstituted aryl radical, R.sup.4-Y and R.sup.4'-Y', together, can also be substituted or unsubstituted, saturated or unsaturated or aromatic, 5- or 6-member ring with 0 to 2 oxygen, sulfur atoms and/or --NR.sup.11 -- groups, k is 0, 1 or 2, and n is 0 or 1, with the proviso that for group V, k and n are greater than 0 only if R.sup.11 is a C.sub.1 -C.sub.8 -alkyl radical; ring A is ##STR42## wherein M and N, together, are a second bond, or M is hydrogen and N is hydroxy, in which case B, R.sup.2, G, R.sup.3, D and E are all each hydrogen, X is an oxygen atom, two hydrogen atoms or one hydroxyimino group (N--OH), R.sup.3 and D, being the same or different, are each hydrogen nitrile, or C.sub.1 -C.sub.4 -alkyl radical, R.sup.3 and D, together, can also be a methylene or ethylene group, E is hydrogen or C.sub.1 -C.sub.4 -alkyl radical, D and E, together, can also be a second bond between carbon atoms 1 or 2 or, together, can also be a methylene group; or Ring A is ##STR43## or Ring A is ##STR44## wherein R.sup.11 is hydrogen or C.sub.1 -C.sub.8 -alkyl radical; and pharmaceutically tolerated acid addition salts thereof.
18. A compound according to claim 17, wherein M and N together are a double bond.
19. A compound according to claim 17, wherein X is an oxygen atom.
20. A compound according to claim 17, wherein X is N.about.OH.
21. A compound according to claim 17, wherein D and E together are a double bond.
22. A compound according to claim 17, wherein B and G together are a double bond.
23. A compound according to claim 17, wherein R.sup.2 is chlorine.
24. A compound according to claim 17, wherein G is methyl.
25. A compound according to claim 17, wherein B and R.sup.2 together are methylene.
26. A compound according to claim 17, wherein X is two hydrogen atoms.
27. A compound according to claim 17, wherein M and N together are a double bond and X is an oxygen atom.
Patent Citations (2)
| Patent | Date | Inventor | Cited By |
|---|---|---|---|
| US4447424 | 1984-05-01 | Teutsch et al. | |
| EPX188396 | 1986-07-01 |
Non-Patent Literature (2)
- Morrison et al., Organic Chemistry, 3rd Ed., Allyn & Bacon, Inc., Boston, pp. 622 and 631 (1979).
- Stork et al., "Cyclization of Vinyl Radicals: A New Versatile Method for the Construction of Five- and Six-Membered Rings", J. Am. Chem. Soc., 104:2321-2323 (1982).